WO2002021108A2 - Method for detecting molecules or chemical reactions by determining variation of conductance - Google Patents

Method for detecting molecules or chemical reactions by determining variation of conductance Download PDF

Info

Publication number
WO2002021108A2
WO2002021108A2 PCT/US2001/027529 US0127529W WO0221108A2 WO 2002021108 A2 WO2002021108 A2 WO 2002021108A2 US 0127529 W US0127529 W US 0127529W WO 0221108 A2 WO0221108 A2 WO 0221108A2
Authority
WO
WIPO (PCT)
Prior art keywords
light
sample
particles
centrifuge tube
ofthe
Prior art date
Application number
PCT/US2001/027529
Other languages
French (fr)
Other versions
WO2002021108A3 (en
Inventor
Norman G. Anderson
N. Leigh Anderson
Original Assignee
Large Scale Proteomics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Large Scale Proteomics Corporation filed Critical Large Scale Proteomics Corporation
Priority to AU2001288762A priority Critical patent/AU2001288762A1/en
Publication of WO2002021108A2 publication Critical patent/WO2002021108A2/en
Publication of WO2002021108A3 publication Critical patent/WO2002021108A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47Scattering, i.e. diffuse reflection
    • G01N21/49Scattering, i.e. diffuse reflection within a body or fluid
    • G01N21/51Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/645Specially adapted constructive features of fluorimeters
    • G01N21/6456Spatial resolved fluorescence measurements; Imaging
    • G01N21/6458Fluorescence microscopy

Definitions

  • the present invention relates to the field of separating and identifying microorganisms, particularly infectious agents, using two-dimensional centrifiigation and exposure to chemical and enzymatic agents, combined with detection in density gradients based on light scatter or fluorescence, counting by fluorescence flow cytometry, and characterization of intact virions, bacteria, proteins and nucleic acids by mass spectrometry, flow cytometry and epifluorescence microscopy.
  • DNA and RNA in both active and fixed bacterial and viral particles have been stained with fluorescent dyes specific to nucleic acids, and observed and counted by fluorescent microscopy and flow cytometry.
  • fluorescent dyes specific to nucleic acids, and observed and counted by fluorescent microscopy and flow cytometry.
  • Many dyes are now known which exhibit little fluorescence in the free state, but become highly fluorescent when bound to nucleic acids. Some bind differentially to DNA or RNA or to different specific regions, and some show different emission spectra depending on whether bound to DNA or RNA.
  • dyes referred to are fluorescent dyes'. By differential fluorescence spectroscopy ssDNA, dsDNA and RNA may be distinguished.
  • Isolated nucleic acid molecules ofthe dimensions found in bacteria and viruses have been counted and their mass estimated using fluorescence flow cytometry for molecules in solution, and epifluorescence microscopy of immobilized molecules (Hennes and Suttle, 1995, Goodwin et al., 1993).
  • the size of fragments produced by restriction enzymes can be estimated, and the molecules identified by reference to a database listing the sizes of fragments of known DNA molecules produced by different restriction enzymes (Hammond et al., U.S. Patent No. 5,558,998; Jing et al., 1998).
  • MALDI- TOF-MS Matrix- Assisted Laser-Desorption-Ionization Time-of-Flight Mass Spectrometry
  • MALDI- TOF-MS Matrix- Assisted Laser-Desorption-Ionization Time-of-Flight Mass Spectrometry
  • TOF-MS currently used methods require a picomole or more of protein, while electrospray mass spectrometry currently requires 5-10 femtomoles.
  • the detection limits with mass spectrometry, especially MALDI depend on getting a sample concentrated and on to a very small target area. Sensitivity will increase as ultramicro methods for concentrating and transferring ever smaller- volume samples are developed. See, Claydon et al., 1996; Fenselau, 1994; Krishmanurthy et al.,
  • centrifuge tubes disclosed in the prior art which include a shape similar to that ofthe microbanding centrifuge tubes ofthe instant invention could not withstand the centrifugal forces required to band viral particles in gradients.
  • Conventional centrifuge tubes, or tubes derivative from the Sutherland design have been used for density gradient separations, and for separations in which wax or plastic barriers are used which position themselves between regions of different density to allow recovery of these fractions without mixing.
  • barriers which prevent mixing of step gradient components at rest, but which barriers are centrifuged away from the gradient during rotation.
  • tube closures for high-speed thin-walled swinging-bucket centrifuge tubes been described, whose exterior surfaces can be disinfected after the tubes are loaded.
  • viruses and bacteria are often resistant to the actions of detergents and enzymes which will digest or dissolve contaminating particles of biological origin, and efforts have been made to classify infectious agents on the basis of their differential sensitivities. These differences have not previously and conveniently been incorporated in a method for detecting and quantifying infectious agents. See, Gessler et al., 1956; Theiler, 1957; Epstein and Hold, 1958; Kovacs, 1962; Planterose et al., 1962; Gard and Maaloe, 1959. Density differences between different species of virus and bacteria are well known, but have not been previously exploited for purposes of identification.
  • Infectious particles exhibit a wide range of isopycnic banding densities ranging from approximately 1.17 g/ml to 1.55 g/ml, depending on the type of nucleic acid present, and the ratios between the amount of nucleic acid, protein, carbohydrate, and lipid present. While such banding density differences are well known, no attempt has been previously made to systematically measure them and use the data to classify infectious agents.
  • the present invention is directed to an integrated system for concentrating, detecting and characterizing infectious agents using separations based on sedimentation rate and banding density, spectral analysis of emitted fluorescent light to distinguish DNA from RNA, differentiation of viral and bacterial particles from other particles by sedimentation through zones of solubilizing enzymes or reagents, determination ofthe isopycnic banding densities of infectious particles by reference to the positions of synthetic density standardization particles, particle detection using fluorescent dyes for DNA or RNA, further concentration of banded particles by pelleting, transfer of concentrated particles to mass spectrometer targets for protein mass determination and analysis, counting of concentrated particles by epifluorescent microscopy and fluorescence flow cytometry, and identification of bacterial or viral nucleic acids by restriction fragment length polymorphism analysis using either immobilized nucleic acid molecules, or ultrasensitive fluorescence flow cytometry. These methods are especially useful in characterizing biological samples which have low titres of virus and which contain viruses which are not culturable.
  • the present invention is further directed to a method and apparatus for measuring light scatter from a microbanding zone.
  • the overall obj ective of this invention is to develop a physical system for rapidly identifying infectious disease agents without growing them, and for discovering new infectious agents.
  • infectious agents constitute a unique group of particles which can be isolated by physical and chemical means from other natural particles and identified by their physical parameters using centrifugal means, light scatter, fluorescence, and mass spectrometry.
  • the system will allow rapid clinical distinction between viral and bacterial infections, identification of specific agents with the aim of providing specific therapy, and the rapid discovery of new infectious agents.
  • the system will make it feasible to develop and test new antibiotics and antiviral agents in man by measuring the effects of these agents on bacterial and viral loads.
  • new antiviral drugs is severely hindered by inability to define populations of individuals in the early stages of infection who might benefit from treatment.
  • an ultracentrifuge tube which comprises upper, middle and lower regions of successively smaller diameters.
  • the tube has an upper region for receiving a sample, a funnel-shaped middle region and a lower narrow tubular microbanding region.
  • the diameter ofthe lower region may be 0.25 inch or less, preferably 0.1 inch or less, more preferably 0.1 to 0.08 inch, and most preferably 0.08 to 0.039 inch. Smaller diameter microbanding regions are feasible and are within the province of this disclosure.
  • the length ofthe lower region is typically between 5% to 25% of the length ofthe tube.
  • the tube may also include a seal with a central opening which can be plugged and unplugged.
  • a bucket for holding an ultracentrifuge tube.
  • the bucket comprises upper and lower regions which may be of successively smaller diameters, may have inserts to successively decrease the inner diameter, or may be of uniform internal diameter, and may further comprise a third region which attaches the bucket to a rotor.
  • a method for concentrating microorganisms.
  • microorganisms is intended to include viruses, mycoplasmas, rickertsia, yeast and bacteria.
  • the method comprises ulfracentrifugation of a sample containing the microorganism in an ultracentrifuge tube described herein.
  • the ulfracentrifugation may include the formation of density gradients and/or the staining ofthe microorganism(s).
  • the staining can be used to distinguish the DNA or RNA content of a virus.
  • the banding of the microorganisms upon ulfracentrifugation can be used to identify the microorganisms.
  • the concentrated microorganisms are further characterized by conventional techniques such as mass spectrometry, flow cytometry, optical mapping, isopycnic banding densities, light scattering, fluorescence, restriction enzyme analysis, genome size, enzymatic or chemical resistance/susceptibility, immunochemistry and the like.
  • the amount or titre ofthe microorganisms can be determined.
  • a system for measuring light scatter and fluorescence from a sample in a centrifuge tube.
  • the system includes a centrifuge tube, a light source, such as a laser, and a detector to detect light passing through the sample or emitted or scattered from the sample upon light passing through it.
  • Optical filters select and separate the exciting and emitted or scattered wavelengths of light.
  • the internal surfaces ofthe tubes and especially the funnel portion must be very smooth in order to prevent small virus particles from being retarded by surface irregularities and, in addition, the surfaces must be treated so that infectious particles are not adsorbed. Polishing of plastic surfaces is done by brief exposure to a solvent vapor. For example, polycarbonate is polished by brief exposure to heated methylene chloride gas.
  • Plastic surfaces are modified to prevent adsorption of infectious particles by exposure to dilute solutions of proteins such as bovine serum albumin or gelatin, or to charged polymers such as heparin or derivatives of heparin. Both of these procedures are well known to those practiced in the arts.
  • a system for counting particles concentrated in a small volume.
  • the system includes a container in which the particles are concentrated, a capillary tube, two pumps, means for moving the container relative to the capillary tube, a flow cell, a light source and detector.
  • fluid may be moved by gas pressure instead of pumps.
  • Figure 1 shows an S-rho plot for a typical tissue and for representative viruses.
  • Figures 2A-2C are a diagrammatic representation of one embodiment of a centrifugal microbanding tube and its use.
  • Figures 3A-3G show alternative embodiments of microbanding tubes and use in a rotor (3F).
  • Figures 4A and 4B illustrate a centrifuge swinging bucket design that allows higher speed fractionation of large sample volumes.
  • Figure 5 illustrates a complete system including vertical monochromatric laser illumination, goniometer and X-Y stage for supporting and positioning microbanding tube, microbanding tube with banded viruses particles, and camera system.
  • Figure 6 illustrates a complete system including interference filter light sources, light pipe illumination, digital data acquisition, and CRT data presentation.
  • Figure 7 illustrates a method for recovering banded virus particles using a micropipette, and counting them by flow cytometry.
  • Figures 8A-8C illustrate details of band recovery.
  • Figures 9A-9F illustrate one embodiment of a closure for swinging bucket rotor centrifuge tubes and detection of a sample with respect to the tubes.
  • Figure 10 illustrates a complete system that is similar to the system depicted in Figure 5, the system in Figure 10 used to measure light scatter in accordance with the present invention.
  • Figure 11 is a computer generated graph indicating the intensity of measured light scatter from a microbanding zone in a centrifuge tube in accordance with the present invention.
  • Figure 12 is an image from the camera ofthe system depicted in Figure 10 showing the light scatter from the microbanding zone in the centrifuge tube in accordance with the present invention.
  • Figure 13 is a computer generated graph indicating the intensity of measured fluorescence from the microbanding zone in the centrifuge tube in accordance with the present invention.
  • Figure 14 is an image from the camera of the system depicted in Figure 10 showing the fluorescence from the microbanding zone in the centrifuge tube in accordance with the present invention.
  • Figure 15 is a schematic drawing showing the system depicted in Figure 10, with elements removed to provide greater clarity and show the orientation ofthe polarized light from the laser in accordance with the present invention.
  • Figure 16 is another schematic drawing showing the system depicted in Figure 10, with elements removed to provide greater clarity, and showing moveable filters that enable the system to measure both light scatter and fluorescence in accordance with the present invention.
  • the invention is directed to methods of identifying and measuring the presence of microbial agents such as bacteria and viruses in biological samples.
  • the methods include centrifugation steps to purify the microbial agents in a very small volume.
  • the agents are then assayed by means such as isopycnic banding density, light scatter detection, fluorescence or mass spectrometry.
  • reagents including detergents, surfactants, enzymes, or organic solvents contained in distinct zones in a density gradient to dissolve or disassemble contaminating particles to prevent them from banding with the microorganisms, and to separate stained particles from the free stain ofthe initial sample volume.
  • the banding gradient which is typically 0.04 mL, to approximately 4 mL in water or a very dilute buffer
  • the invention will be described with reference to viruses as the microorganisms. It will be understood that the invention is also applicable to other microorganisms, including mycoplasmas, yeast and bacteria. The invention is particularly suited for the identification of infectious agents, and will be described in this context.
  • Figure 1 is a graph depicting the sedimentation coefficients and isopycnic banding densities of subcellular organelles and viruses to illustrate the concept ofthe "Virus Window” (Anderson, 1966). It is evident that viruses have a relatively narrow range of sedimentation coefficients and banding densities and may be isolated from a tissue homogenate or from blood in a high state of purity using high resolution S-p separation systems.
  • high resolution S-p centrifugal methods and of centrifuge development for virus isolation refer to National Cancer Institute Monograph 21, The Development of Zonal Centrifuges and Ancillary Systems for Tissue Fractionation and Analysis, U.S. Department of Health, Education and Welfare, Public Health Service, 1966.
  • RNA virus would contain 6.022 x 10 ⁇ viral particles, while 6 x 10 9 virions would contain 1 picomole of a viral coat protein present in 100 copies per virion.
  • Quantitative polymerase chain reaction PCR has been used to demonstrate that in many infectious diseases > 10 8 virus particles are present per mL of plasma or serum.
  • PCR quantitative polymerase chain reaction
  • individual viral proteins can be detected using MALDI-TOF-MS (Krislimanurthy et al., 1996; Holland et al., 1996).
  • samples containing 10 6 virus particles/mL can be detected, while with flow cytometry and immobilized DNA epifluorescence microscopy, even fewer particles are required (Hara et al., 1991; Hennes and Suttle 1995).
  • the application of these methods to bacteria may require a preseparation of proteins to reduce the complexity ofthe sample.
  • detection has been by charged ion detection, and the limitations of such detection have set the upper limits to the size of proteins and nucleic acids that can be detected.
  • Mass spectrometric methods have now been described which allow masses of biological particles above 100,000 daltons to be measured. In order to work with such levels of virus, the virus must be concentrated into a very small volume.
  • FIG. 2A illustrates diagrammatically a hollow transparent centrifuge tube 1 with an upper sample volume 2, grading into a serrated funnel region 3 having successively tapered and parallel-wall sections 4-6, constricting down to a narrow tubular microbanding region 7.
  • the serrated funnel region 3 is an improvement over centrifuge tubes which simply taper from top to bottom without including a serrated region.
  • serrations is meant, for example, concentric rings or edges or lips. These rings, edges or lips are preferably continuous around the inner diameter of the centrifuge tube, but this is not required. For example, three projections from the inner wall of the centrifuge tube spaced equally around the diameter could be used to hold a disk in place.
  • the term serrations is meant to include such possibilities but does not include a straight tapering with no rings, edges, lips or projections on the inner surface ofthe centrifuge tube.
  • the serrations can be used as rests onto which disks can be placed to separate two or more layers of liquid. Although disks can be placed into tubes which simply taper without serrations, the disks in such tapered tubes can be easily tipped up on one edge by pushing down on the opposing edge.
  • the centrifuge tube may be 3.45 inches from top to bottom, have an outer diameter at the top of 0.562 inch, and have an inner diameter in the bottom microbanding region 7 of 0.064 inch.
  • Such a tube is suitable for use in an SW41 Ti (Beckman) rotor.
  • the inside surface of the tube is preferably polished using conventional techniques, including vapor polishing, so that the virus particles do not stick to the wall ofthe tube.
  • the internal surfaces ofthe tubes may be coated with a protein or polymer to prevent particle adhesion, as is well known in the art.
  • Figure 2B illustrates how the tube is loaded at rest with a series of fluids of decreasing physical density.
  • the tube shown comprises a series of serrations onto which can be laid disks to separate one layer of fluid from the next layer of fluid.
  • Liquid 8 is denser than any particle to be recovered, and is used to partially fill the microbanding region 7.
  • an air bubble 10 (wherein by air is meant atmospheric air or another gas) may be left to keep the fluids 8 and 9 separate.
  • air bubble 12 may be left in place, thus keeping the three liquids separate until centrifugation is commenced.
  • a tube with an inner diameter of 0.064 inches in microbanding region 7 is suitable for allowing an air bubble to be left in place to separate two layers of liquid. Alternatively, the air bubbles may be left out and the fluids allowed to diffuse together to create a density gradient.
  • Fluid 11 is covered with a light porous plastic disk 13, preferably of sintered polyethylene or polypropylene, which fits in place in the first serration.
  • a fluid 14, less dense than fluid 11, which may contain one or more reagents, is then introduced, and covered with disk 15, followed by even less dense liquid 16 which is covered with disk 17. The entire system is stable until centrifuged. Before use the sample layer 18, which has a density less than that of fluid 16 is then added up to level 19.
  • the tubes are then centrifuged at high speed in metal shields, typically with water or other liquid added to the shields.
  • the tubes may be supported by fitting adapters which fill the space between the tubes and the shields, and water may be added to fill any spaces between the tubes, adapters and shields to provide additional support.
  • the tubes may be capped (as shown in Figures 9A-9F, described in further detail below), to minimize the chances of operator infection.
  • Figure 2C illustrates diagrammatically a tube after centrifugation.
  • the porous separation disks 13, 15, and 17 have risen to the top ofthe tube, and sample layer 18 is cleared of virus, and the original step gradient has changed, by diffusion, into one of a series of shallow gradients.
  • gas bubbles 10 and 12 have also moved centripetally, and fluids 8 and 9 have come into contact to form a steep gradient by diffusion.
  • the slope of this gradient diminishes, producing a banding gradient of a width suitable for banding the infectious agents.
  • the densities typically range from 1.18 to 1.55 g/ml.
  • These gradient steps may not only contain reagents to dissolve non- viral particles, but also serve to wash excess fluorescent dye away from the particles.
  • various detergents or enzymes such as proteases may be added either to the sample layer 18 or to other layers such as 14 or 16. Fluorescent dyes may also be present in these regions. The free dye will not enter the lower, more dense regions in which the virus bands and therefore the centrifugation will purify the viruses from all of the reagents which may be present in the upper, less dense layers.
  • the microbanding region ofthe tube contains the upper portion ofthe banding gradient 27, banded virus 28 (including any dye bound to the virus or viral nucleic acid) and lower dense portion of the banding gradient 29, and the gradient formed between them by diffusion.
  • Figures 3A-3G illustrate alternative embodiments of tubes useful for microbanding of viruses and bacteria and all have a serrated internal construction which allows one or more light barriers to be positioned and retained at rest.
  • Tubes shown in Figures 3A-3D and 3G are designed to be centrifuged in swinging bucket rotors so that the tubes are horizontal during centrifugation and vertical at rest.
  • the tube shown in Figure 3A is the more conventional design with a sample reservoir 31, a serrated funnel region 32, and a microbanding section 33.
  • the tube shown in Figure 3B is similar to that of Figure 3 A, but it is supported in a centrifuge shield by a support insert 34 which may be of plastic or metal.
  • the tubes shown in Figures 3B-3E fill a rotor chamber completely.
  • the tube of Figure 3C has an opaque bottom section 35 which absorbs scattered light, while that shown in Figure 3D has a bulbous section 36 at the bottom ofthe microbanding tube 37 to contain an excess volume ofthe fluid forming the dense end ofthe gradient, thus stabilizing the gradient.
  • the tube shown in Figure 3E is designed to be centrifuged in an angle head rotor as shown in Figure 3F, and has a linearly continuous wall 38 along one side positioned in the rotor so that particles may readily slide down to microbanding region 40.
  • the tube shown in Figure 3G illustrates how a very large microbanding tube may be fabricated.
  • Figures 4A-4B illustrate how the tube of Figure 3G may be centrifuged at higher speed than tubes having a constant radius from top to curved bottom.
  • This is accomplished by using a metal, plastic or carbon fiber shield 45 which matches the dimensions of tube 46.
  • the shield has a cap 47 and the shield or bucket swings on integral attachment 48, as is conventionally done in high speed swinging bucket rotors.
  • Tip 49 ofthe shield is much smaller diameter than the upper section ofthe shield, has much less mass swinging at its maximum radius, and hence can reach much higher speeds than is the case with shields of uniform internal diameter. This makes possible isolation of trace amounts of virus from much larger volumes than would otherwise be the case.
  • shield and tube 52 assume a horizontal position as shown.
  • the microbanded viruses can be analyzed at this stage or they can be collected, diluted, and further processed. To analyze the microbanded viruses at this stage, they can be detected by a system as shown in Figure 5.
  • the isopycnic banding step or an earlier step may have included a fluorescent dye or fluorescent dyes within the solution with which the virus was mixed or through which the virus was centrifuged. Dyes are known with which intact viruses may be stained and which can distinguish between RNA, DNA, single stranded nucleic acid and double stranded nucleic acid thereby allowing one to detect the presence or absence of an infectious agent, and further to determine which type of virus one has purified.
  • the apparatus of Figure 5 can be used to analyze these stained particles.
  • a scanning and detection system is illustrated schematically in Figure 5 where microbanding tube 60 is held in a vertical position on mount 61 supported by goniometers 62 and 63 which are in turn supported by X-Y movements 64 and 65 in such a manner as to align and center the microbanding section of tube 60 with respect to laser beam 66.
  • Laser beam 66 is generated by a laser 67, which may be an argon ion laser producing coherent light at 458, 488, 496, 502, and 515 nm.
  • the beam passes through an interference or other filter 68 to isolate one wavelength, and is reflected down into the microbanding tube by dichroic mirror 69.
  • the fluorescent banded particle zone 70 is photographed or electronically scanned by camera 71 through emission filter 72.
  • the entire system may be enclosed to eliminate stray light, and filters 68 and 72 may be replaced by filter wheels (not shown) to optimize detection using fluorescent dyes which absorb and emit at different wavelengths, or to distinguish ssDNA, dsDNA and RNA by differences in the spectra of emitted fluorescent light.
  • Electronic shutters may be attached to the laser to minimize sample exposure to light and to the camera to control exposure.
  • the goniometers and X-Y movements may also be motor driven and remotely controlled, and the entire system may be controlled by a computer (not shown).
  • FIG. 6 illustrates a different version of the scanning system which can cover all of the visible spectrum and on into the near ultraviolet.
  • Microbanding tube 80 is aligned in a fixed support between transparent intensity equihbrators 81 and 82 attached to light pipes 83 and 84 which are in turn attached to intensity equilibrator 85 illuminated through filter 86 by condensing lens 87 and - light source 88.
  • Filter 86 is one of a set attached to filter wheel 89 indexed by motor 90. The result is uniform illumination from two sides of one or more bands 91, 92 and 93.
  • the image is captured through emission filter 94 by digital camera 95 and the image stored, processed and displayed by computer 96 on CRT 97.
  • Filter 94 may be replaced by a filter wheel identical to 89 and 90 so that, with both an excitation filter wheel and an emission filter wheel and a wide spectrum light source such as a xenon lamp or a halogen lamp, a wide variety of combination of exciting and emitting light may be chosen, which in turn makes possible use of a wide variety of fluorescent dyes. Both fluorescent light and light scatter at a chosen wavelength may be employed for particle detection.
  • This arrangement facilitates distinction between ssDNA, dsDNA and RNA.
  • the processed image 98 may be displayed to show a picture ofthe tube and contained bands 99, 100 and 101.
  • the amount of light from each band may be integrated and displayed as peaks 102, 103, and 104, and in addition the integrated values may be displayed digitally (not shown).
  • the entire system including shutters on the light source and camera (not shown), filter movement and positioning, and focusing ofthe camera may be digitally controlled by computer 96.
  • Display bands 99 and 101 representing centrifuge tube bands 91 and 93 may be fluorescent or non-fluorescent density marker beads of known density, and the virus band 92 represented by display band 103.
  • the banding density ofthe virus may be determined by interpolation from the positions ofthe density markers. When non-fluorescent density markers are used, these are detected by scattered light using identical filters at positions 86 and 94. A second image using suitable and different filters is then captured which is comprised solely of fluorescent light. The two images are electronically inter-compared and the physical density of the infectious agent determined by interpolation.
  • the virus can be identified as being a DNA virus or an RNA virus, and if a
  • DNA virus it can be determined whether it is single stranded or double stranded. Furthermore, the density of the virus can be determined. This data can be used to help identify the type of virus which has been purified. Nevertheless, it may be desirable or necessary to gather more data to fully determine what the exact virus is and also to determine the original viral titre.
  • Figure 7 illustrates diagrammatically counting of individual fluorescent particles recovered from a tube 110 containing zones of banded virus 111 and 112 after all fluid above the banding gradient has been removed and replaced.
  • the tube is placed in a tube holder 113, and an overlay of deionized water or very dilute buffer 114 is introduced above the gradient supplied through tube 115 to replace the volume drawn up in the probe 117.
  • the tube may be closed at the top by a plastic closure 116.
  • the capillary probe 117 is held stationary, and the microbanding tube 110 is slowly raised under it.
  • the tube holder 113 is part of a precision drive mechanism 118 and associated stepping motor 119 that moves the tube holder vertically at a very slow and controllable rate.
  • a slow steady stream of fluid is drawn into constriction 120 which is centered in sheath stream 121 provided by pump 122.
  • the result is a constant flow of fluid through flow cell 123 with a fine virus containing stream in the center, elongated and extended by the flowing sheath.
  • a second pump 124 withdraws fluid upward at a constant rate from the flow cell, which rate is greater than the rate at which piston pump 122 injects fluid into sheath 121. The difference in the rates of pumps 124 and
  • the fluid coming through capillary probe 117 is a mixture of virus plus fluid from the overlay which is introduced via tube 115.
  • the flow cell 123 is illuminated by laser beam 125 produced by laser 126, that passes through exciting filter 127. Emitted light is isolated by emission filter 128 and detected by a photomultipher 129. The output from the photomultipher 129 is integrated at intervals by computer 130, and the integrated signal vs. time is displayed on CRT 131. When two viral bands are present, two peaks such as 132 and 133, are displayed. Depending on the number of fluorescent particles present, the signal generated from a band may be integrated into a peak, or, if the suspension is sufficiently dilute, the particles may be counted individually, the values binned, and the integrated results displayed.
  • Figure 8 illustrates diagrammatically how the problem of making an initial dilution of a very small-volume virus band for counting individual particles is accomplished.
  • Figure 8 A shows a tube 110 as in Figure 7, with a section indicated which is shown enlarged in Figure 8B, which in turn shows the section of that panel enlarged in
  • a sharp band of virus particles 144 is diluted and moves through the flow cell as, volumetrically, a larger band, but with little effective loss of resolution.
  • This technique provides the dilution necessary to make counting of individual virus particles feasible and accurate.
  • the amount of dilution can be controlled such that the concentration of microorganisms in the capillary tube is less than one-half or one-tenth, or one-hundredth, or one-thousandth, or one ten-thousandth, or one-millionth, or one-billionth ofthe concentration in the band in the lower region of said tube.
  • the amount of DNA in the virus or other microbe can be determined for individual particles.
  • the amount of DNA in the particles is measured by flow fluorescence analysis (Goodwin et al., 1993) or epifluorescence analysis (Jing et al., 1998).
  • yeast, bacteria, mycoplasma and virus can be distinguished as groups, For example, it is known that viruses contain 5-200 x 10 3 bases or base pairs, E. coli, a typical bacterium, contains 4 x 10 6 base pairs, while a typical yeast cell contains 1.3 x 10 7 base pairs.
  • an estimate ofthe amount of DNA or RNA present allows the class of an infectious agent to be determined.
  • the size of a genome can be determined.
  • the genome is extracted from the microorganism band and immobilized on a solid support.
  • the immobilized DNA is stained and electronically imaged using an epifluorescence microscope (Jing et al., 1998). The length ofthe individual nucleic acid molecules can then be measured.
  • microbanding is useful not merely for staining the virus with dyes and being able to count the virus particles.
  • the band When an infectious agent is banded in a microbanding tube, the band may also be judiciously removed using a capillary needle in a volume of a few micro liters, diluted to 5 mL or more with very dilute buffer or deionized water to dilute the gradient materials by a factor as large as 1,000, and then pelleted in a fresh microbanding tube. The supernatant may then be carefully withdrawn by a suction capillary, and the virus or other agent resuspended in approximately 1 microliter using a syringe made, for example, of fine Teflon® tubing fitted with a very small stainless steel wire plunger to fit.
  • a syringe made, for example, of fine Teflon® tubing fitted with a very small stainless steel wire plunger to fit.
  • the sample may then be transferred to a mass spectrometer target, mixed with a matrix dye, and used for matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) to determine directly the masses of viral coat proteins or of bacterial cell proteins.
  • MALDI-TOF-MS matrix assisted laser desorption ionization time of flight mass spectrometry
  • Technology described for sample concentration may also be applied, without a matrix dye, to electrospray or other mass spectrometric analysis systems, including the detection of intact viral mass.
  • a system similar to that shown in Figure 7 may also be used to produce the equivalent of molecular restriction fragment length maps of DNA molecules using restriction enzymes.
  • virus or bacterial particle bands may be diluted and sedimented as described, after which the DNA may be extracted using detergents or other reagents well known in the art, treated with a restriction enzyme and a fluorescent dye, and the fragment sizes determined by flow cytometry (Goodwin et al., 1993; Hammond et al, U.S. Patent No. 5,558,998).
  • Extracted DNA may also be immobilized on a solid support, stained with a fluorescent dye, and photographed using an epifluorescence microscope to determine the length of DNA molecules.
  • the preparation may then be treated with a restriction endonuclease, and the number and lengths of the oligonucleotide fragments determined (Jing et al., 1998). These data are then compared with a database listing the expected fragment lengths for different viral or bacterial species to identify each agent. DNA fragment lengths may also be determined by gel electrophoresis.
  • Fluorescence labeled antibodies may also be added to the particle suspension studied, and the presence or absence ofthe label in isopycnically banded particles determined. This approach is useful for specific identifications, and the use of a set of antibodies labeled with dyes having different and unique spectral characteristics allows the presence or absence of a series of agents to be determined. Alternatively antibodies labeled with chelators for rare earth's such as Europium and Terbium may be employed, in which case delayed fluorescence is measured. Serum or plasma typically has a physical density between 1.026 and 1.031.
  • Viruses typically have banding densities between 1.17 and 1.55 in cesium chloride, and at much lower densities in iodinated gradient materials such as lodixanol or sucrose (Graham et al., 1994).
  • the intermediate wash and reagent layers between the sample and the banding gradient must therefore have densities less than the density ofthe lightest virus to be banded.
  • Buffers used to dissolve gradient material for virus isolation include 0.05 M sodium borate, and 0.02 M sodium cyanide, both of which prevent bacterial growth.
  • fluorescent particles of known density may be included in the sample as shown in Figure 6. These particles may include known fixed and fluorescently stained virus or bacterial particles of known banding density, or very small fluorescently labeled or non-fluorescently labeled plastic beads.
  • polystyrene latex particles When polystyrene latex particles are coated with antibodies, their banding densities are increased appreciably, and the density may be further increased by reaction of the antibody-coated particles with the antigen for which the antibodies are specific (Anderson and Breillatt, 1971). Antibody-coated fluorescent polystyrene beads may therefore be used not only to locate virus particles but to identify them.
  • High speed centrifuge tubes are notoriously difficult to seal effectively and are a potential source of infection to laboratory personnel.
  • nearly all high speed swinging bucket rotor tubes are not themselves sealed, but are enclosed in a metal bucket which is sealed with a metal cap which does not seal the tube.
  • the centrifuge tubes are therefore open when loaded, moved to the centrifuge rotor, inserted, and removed. It is very difficult to decontaminate the outside of an open tube containing a density gradient without disturbing the gradient.
  • it is desirable to be able to effectively seal the plastic tubes is such a manner that the outside surfaces can be cleaned with a suitable disinfectant before the tubes are inserted into centrifuge shields, and to be able to handle them safely until they are scanned.
  • Sealing is done, as shown in Figure 9A, by inserting an annular ring seal 151, having a physical density less than that of water, into tube 152.
  • Ring 151 is slightly tapered so that it fits very tightly into tube 152, and has a center hole which can be plugged and unplugged.
  • the center hole is threaded to accept a short, plastic flat-head screw.
  • two gradient components including a lighter solution 153 and a denser solution 155, are introduced to the bottom microbanding region with a small air bubble 154 between, as previously described.
  • the solution 156 containing the infectious agent or other particles is then introduced through tube 157, leaving bubble 158 to separate the sample from the upper gradient solution.
  • the volume of sample introduced does not completely fill the centrifuge tube, leaving space 159 empty.
  • the tube is then sealed, as shown in Figure 9C with, for example, a plastic flat head screw 160, leaving air bubble 160 in place.
  • the outside of the tube is then sterilized by immersing it in a disinfectant such as a sodium hypochlorite or hydrogen peroxide solution, followed by a water wash and gentle drying - all with the tube in an upright position.
  • a disinfectant such as a sodium hypochlorite or hydrogen peroxide solution
  • the seal since the seal has a density less than water, it is retained at the top ofthe liquid sample, leaving a small lip 160 which may be grasped with a hemostat to remove the tube from the centrifuge shield. During centrifugation, the infectious particles are sedimented out of liquid 163 and produce band 164 in the gradient. The screw in the ring seal is then removed, and, as shown in Figure 9E, the supernatant liquid 165, which may contain a fluorescent dye, is removed through tube 166, leaving meniscus 167. As shown in Figure 9F, a laser beam 168, entering the tube from above, is then aligned with the tube, causing the banded infectious agent to emit fluorescent light for detection as previously described.
  • the laser or delayed fluorescence systems can be completely contained, the mechanical operations done remotely through small stepping motors, and the tubes moved in and out of the contained system under remote control.
  • An alternate embodiment of a virus detecting system is configured to detect viruses without the use of a dye, such as the fluorescent dyes mentioned above with respect to the system depicted in Figure 5.
  • the virus detecting system depicted in Figure 10 includes many ofthe components ofthe system in Figure 5, but instead of detecting fluorescence from a fluorescent dye, the system in Figure 10 measures scattered light emitted from the microbanded viruses.
  • the scanning and detection system illustrated schematically in Figure 10 includes a mount 61 that supports a microbanding tube 60 in a vertical position.
  • the mount 61 is supported by goniometers 62 and 63 which are in turn supported by X-Y movements 64 and 65 in such a manner as to align and center the microbanding section of tube 60 with respect to a laser beam 66.
  • the X-Y movements 64 and 65 are for orthogonal adjustments in a horizontal plane.
  • the goniometers 62 and 63 are each adjustable about perpendicular conical surfaces that have center lines that pass though a portion ofthe tube 60.
  • the laser beam 66 is generated by a laser 67, which may be an argon ion laser producing, for instance, coherent light at 458, 488, 496, 502, and 515 nm.
  • a laser 67 which may be an argon ion laser producing, for instance, coherent light at 458, 488, 496, 502, and 515 nm.
  • One such laser producing device is the Omnichrome 5025 which is an argon laser.
  • Some lasers include internal filters or other internal wavelength determining means such that only a selected wavelength of light is emitted from the laser. For such lasers, no external filter is necessary for producing coherent light at a single frequency, although external filters may be used if desired or if necessary for using a different laser light source.
  • polarized light is desirable and therefore the laser beam 66 may alternatively be provided by any laser light source that produces polarized light at a single frequency.
  • the inventor has determined that smaller wavelengths are more advantageous in the light scattering measurement ofthe present invention. Specifically, a frequency of polarized laser light at 488 nm produces optimal results, as is explained in greater detail below.
  • the laser beam 66 is reflected down into the microbanding tube 60 by dichroic mirror 69.
  • a banded particle zone 70 is photographed or electronically scanned by camera 71 without the need of a filter. The entire system may be enclosed to eliminate stray light.
  • a camera 71 focused on the banded particle zone 70 measures the light scattered therefrom due to the laser beam 66 trained on the particle zone 70.
  • Planar polarized light such as the laser light produced by the laser 67, includes a magnetic component H and an electric component E that are perpendicular to one another. Specifically, for planar polarized light, the electric component E travels in a plane that is perpendicular to the magnetic component H.
  • the orientation of the laser beam 66 is such that as the laser beam 66 passes through the banded particle zone 70, the plane defined by the electric component E is normal (perpendicular) to the line of sight from the camera 71, as is shown in Figure 15. Note that Figure 15 does not include the tube 60 in order to provide greater clarity, but does show the banded zone 70.
  • Example 1 To illustrate the use of microbanding tubes, experimental studies have been carried out using a small single-stranded non-pathogenic DNA virus ⁇ X 174. Approximately 10 10 virus particles which had been purified by isopycnic banding in CsCl in a microbanding tube such as shown in
  • Figure 2A were suspended in 5 mL of 0.05 M borate buffer, were pelleted in a microbanding tube at 35,000 rpm in a swinging bucket rotor, and were resuspended in approximately 3 ⁇ L for analysis.
  • the analyses were done on a PerSeptive Biosystems DESTR instrument with an extraction delay time set at 150 nseconds using a matrix of sinapinic acid.
  • the results are shown in Table 1.
  • the ⁇ X 174 masses for virion capsid proteins F, G, H and J are calculated from published sequence data.
  • J 4,095.78 4,097.03 +1.2 0.03% This example demonstrates that highly purified and concentrated suspensions of microorganisms can be isolated from biological samples such as, but not limited to, patient samples such as plasma, urine, feces and tissues, natural water and tissue culture fluids. This example further demonstrates that such purified and concentrated microorganisms can then be identified, for example, using mass spectrometry to identify viruses.
  • Example 2 The inventor conducted an experiment to demonstrate the greater sensitivity realized by measuring scattered light with the camera 71 focused on a zone 70 with the line of sight of the camera 71 being normal to the plane ofthe electric component E ofthe laser beam 66.
  • lambda phage was purified by banding in cesium chloride and diluted to a titer of 1.5 x 10 10 plaque forming units per mL. 1.5 mL of this preparation was mixed with 25 ⁇ L of 1 mM YOYO-1 fluorescent DNA stain (marketed by Molecular Probes, IN), and left at refrigerator temperature for three days.
  • Parallel sets of microbanding tubes were set up with a step gradient set up in the microbanding region using 17 ⁇ L of room temperature saturated cesium chloride at the bottom, followed by 17 ⁇ L of a 1 :10 dilution ofthe saturated solution in phosphate buffered saline (PBS), pH 7.2. This in turn was followed by 1.5 mL of 1 :20 dilution ofthe same saturated solution in PBS. These solutions were then spaced with small air bubbles, a process made feasible by the very small diameter ofthe microbanding region ofthe tubes 60. Two parallel sets of tubes 60 were then filled, one set with PBS containing 3 x 10 8 stained virions, and the other set with PBS containing 3 x 10 8 unstained virions.
  • PBS phosphate buffered saline
  • All ofthe tubes were then centrifuged for 3 hours at 40,000 rpm in an SW41-Ti rotor in a Beckman L-70K ultracentrifuge.
  • the tubes were vertically illuminated with polarized laser light at 488 nm using an argon ion laser. Images were captured using an Apogee CCD camera. Scatter was measured with both the dyed and non-dyed virus using 488 nm light, while the light emitted by the stained virus was measured using 510 nm light using an interference filter.
  • Figure 12 shows the scatter image generated by the camera 71 of one microbanding zone 70
  • Figure 14 shows the fluorescence image generated by the camera 71 of the same microbanding zone 70
  • Figure 11 shows a computer generated graph ofthe light intensity detected by the camera 71 based upon the image in Figure 12
  • Figure 13 shows a computer generated graph ofthe fluorescent light intensity based upon the image in Figure 14.
  • the intensity units (the numbers on the vertical axis) on the graphs in Figures 11 and 13 are the same. However, the depicted graphs were automatically scaled by the computer to fit a predetermined portion of the computer monitor.
  • the peak height ofthe line scan for scatter was approximately 2300 arbitrary intensity units, while the peak height for the fluorescent virus was only 540 arbitrary intensity units.
  • detection of scatter is more sensitive than detection fluorescence under the conditions employed.
  • An advantage of light scatter measurement is that it is possible to determine the particle size by measuring the angle of maximum light scatter. Therefore, more information is obtainable from measurement of light scatter than from measurement of fluorescence. Further, some fluorescent dyes degrade after exposure to laser light. Light scatter is not affected by duration of exposure to laser light.
  • the inventor has further determined that the shorter the wavelength of light from the laser 67, the greater the amount of scattered light resulting in an increase in sensitivity. Specifically, several ofthe frequencies of polarized light produced by the laser 67 were used, one frequency at a time, in order to measure light scatter from a single microbanding zone 70. A polarized beam of light of 488 nm yielded the best results.
  • the line of sight of the camera 71 is normal (perpendicular) to the plane with the electric component E.
  • the camera 71 is first used to measure quantitatively the light intensity of light scatter from the zone 70 without the filter 72.
  • the filter 68 is required to allow only one frequency of light if the laser 67 outputs several frequencies of light.
  • the filter 72 is moved into position in front of the camera 71 and fluorescence is measured to confirm that the particles are viruses and not, for instance, dust, dirt or other non-essential components. It should be understood that fluorescence measurement is not dependent upon the orientation of polarized light because the fluorescence emitted by the dye is excited by the laser light to emit light and does not necessarily reflect the laser light.
  • Another aspect of the invention is the addition of a polymerizable material, such as acrylamide, in the lower portion ofthe tube 60 that is hardened after centrifugation such that the banded virus may be fixed in position within the tube 60 for later excising and analysis.
  • a polymerizable material such as acrylamide
  • sodium alginate may be introduced into the tube 60 and, after centrifuging, calcium ions may be added to the surface causing the mixture in the tube 60 to gel.
  • the semisolid mass in the tube can be removed, and the zone with the virus removed for further study.
  • the above described methods and apparatus can be used to detect or isolate viruses from plants, animals or environmental sources.

Abstract

A method for separating microorganisms, especially infectious agents, from a mixture by two dimensional centrifugation on the basis of sedimentation rate and isopycnic banding density, for sedimenting such microorganisms through zones of immobilized reagents to which they are resistant, for detecting banded particles by light scatter or fluorescence using nucleic acid specific dyes, and for recovering the banded particles in very small volumes for characterization by mass spectrometry of viral protein subunits and intact viral particles, and by fluorescence flow cytometric determination of both nucleic acid mass and the masses of fragments produced by restriction enzymes. The method is based on the discovery that individual microorganisms, such as bacterial and viral species, are each physically relatively homogeneous, and are distinguishable in their biophysical properties from other biological particles, and from non-biological particles found in nature.

Description

DETECTION AND CHARACTERIZATION OF MICROORGANISMS
CROSS-REFERENCE TO RELATED APPLICATION The present application is a continuation-in-part of application Serial No. 09/265,541 filed
9 March 1999 and is related to U.S. provisional patent application Serial No. 60/077,472, filed on
10 March 1998, both of which are incorporated herein by reference.
This invention was made with Government support under an SBIR grant from NIH, Grant No. 1 R43 AI41819-01/02. The United States government may have certain rights in the invention.
BACKGROUND OF THE INVENTION
The present invention relates to the field of separating and identifying microorganisms, particularly infectious agents, using two-dimensional centrifiigation and exposure to chemical and enzymatic agents, combined with detection in density gradients based on light scatter or fluorescence, counting by fluorescence flow cytometry, and characterization of intact virions, bacteria, proteins and nucleic acids by mass spectrometry, flow cytometry and epifluorescence microscopy.
The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice, are incorporated by reference, and for convenience are respectively grouped in the appended List of References. Patents referenced herein are also incorporated by reference.
In the prior art, diagnosis of viral and bacterial infections has been done by culturing the causal agents in suitable media or in tissue culture to obtain sufficient particles for analysis, followed by identification based on which conditions support growth, on reaction to specific antibodies, or based on nucleic acid hybridization (Gao and Moore, 1996). Biological growth can be omitted when the polymerase chain reaction (PCR) is used to amplify DNA, however, PCR requires sequence-specific primers, and is thus limited to known or suspected agents (Bai et al., 1997). For all these methods, considerable time is required, and the methods are useful for agents whose properties are known or suspected. Existing methods do not provide means for rapidly isolating and characterizing new infectious agents. Hundreds of infectious agents are known, and it is infeasible to have available reagents for an appreciable fraction of them. Techniques for recovering infectious agents from blood, urine, and tissues have been previously developed based on centrifugation or filtration, but have not been widely used clinically (Anderson et al., 1966; Anderson et al., 1967). The highest resolution methods use rate zonal centrifugation to separate fractions based on sedimentation rate (measured in Svedberg units, S) and isopycnic banding density (measured in grams per mL or p). S-p separations have been used to isolate virus particles in a high state of purity from rat liver homogenates, and have been used to isolate the equivalent of approximately 20 virions per cell (Anderson et al., 1966). In these studies, virus particles were detected by light scattering and visualized by electron microscopy. The separations required complex special equipment not generally available, one or more days of effort, and they did not provide a definitive identification ofthe bacterial or viral species separated.
It is important to show that candidate infectious particles isolated by centrifugal methods actually contain nucleic acids. DNA and RNA in both active and fixed bacterial and viral particles have been stained with fluorescent dyes specific to nucleic acids, and observed and counted by fluorescent microscopy and flow cytometry. Many dyes are now known which exhibit little fluorescence in the free state, but become highly fluorescent when bound to nucleic acids. Some bind differentially to DNA or RNA or to different specific regions, and some show different emission spectra depending on whether bound to DNA or RNA. In this disclosure, dyes referred to are fluorescent dyes'. By differential fluorescence spectroscopy ssDNA, dsDNA and RNA may be distinguished. See, Haugland, 1996; Mayor and Diwan, 1961 ; Mayor, 1961; Hobbie et al., 1977; Zimmerman, 1977; Perter and Feig, 1980; Paul, 1982; Suttle, 1993; Hirons et al., 1994; Hennes and
Suttle, 1995; Hennes et al., 1995.
Isolated nucleic acid molecules ofthe dimensions found in bacteria and viruses have been counted and their mass estimated using fluorescence flow cytometry for molecules in solution, and epifluorescence microscopy of immobilized molecules (Hennes and Suttle, 1995, Goodwin et al., 1993). In both instances, the size of fragments produced by restriction enzymes can be estimated, and the molecules identified by reference to a database listing the sizes of fragments of known DNA molecules produced by different restriction enzymes (Hammond et al., U.S. Patent No. 5,558,998; Jing et al., 1998).
Using specific fluorescently-labeled antibodies, specific identifications may also be made. These studies are time consuming, and require batteries of specific antibodies, together with epifluorescent microscopy or fluorimeters. Matrix- Assisted Laser-Desorption-Ionization Time-of-Flight Mass Spectrometry (MALDI- TOF-MS) currently allows precise measurements of the masses of proteins having molecular weights of over 50,000 daltons. Individual virion proteins have been previously studied by mass spectrometry (Siuzdak, 1998); however, resolution of complete sets of viral subunits from clinically relevant preparations of intact viruses, and the demonstration that precise measurements could be made of their individual masses, have not been previously reported. While single protein mass measurements can reliably identify many proteins, when a set of proteins from a virus or bacterial cell are known, detection of such a set provides more definitive identification. Methods are currently also being developed which allow partial sequencing of proteins or enzymatically produced peptide fragments and thus further increase the reliability of identifications. For MALDI-
TOF-MS currently used methods require a picomole or more of protein, while electrospray mass spectrometry currently requires 5-10 femtomoles. The detection limits with mass spectrometry, especially MALDI, depend on getting a sample concentrated and on to a very small target area. Sensitivity will increase as ultramicro methods for concentrating and transferring ever smaller- volume samples are developed. See, Claydon et al., 1996; Fenselau, 1994; Krishmanurthy et al.,
1996; Loo et al., 1997; Lennon and Walsh, 1997; Shevchenko et al, 1996; Holland et al, 1996; Liang et al., 1996.
Centrifugal methods for concentrating particles from large into small volumes have been in use for decades. Using microbanding centrifuge tubes which have a large cylindrical volume and cross section which tapers gradually in a centrifugal direction down to a small tubular section, particles may be concentrated or banded in a density gradient restricted to the narrow tubular bottom ofthe tube, or may be pelleted. The basic designs of such tubes are well known by those skilled in the arts. See, Tinkler and Challenger, 1917; Cross, 1928; ASTM Committee D-2, 1951; Davis and Outenreath, U.S. Patent No. 4,624,835; Kimura, U.S. Patent No. 4,861,477; Levine et al., U.S. Patent No. 5,342,790; Saunders et al., U.S. Patent No. 5,422,018; Saunders, U.S. Patent No.
5,489,396. The original tubes of this type were called Sutherland bulbs and were used to determine the water content of petroleum (The Chemistry of Petroleum and Its Substitutes, 1917, ASTM Tentative Method of Test for Water and Sediment by Means of Centrifuge, ASTM Designation: D 96-50T, 1947). Slight modifications of the basic design are described in U.S. Patent Nos. 4,106,907; 4,624,835; 4,861,477; 5,422,018; and 5,489,396. Such tubes have been made of glass or plastic materials, and the use of water or other fluids to support glass or plastic centrifuge tubes in metal centrifuge shields has long been well known in the art. However, centrifuge tubes disclosed in the prior art which include a shape similar to that ofthe microbanding centrifuge tubes ofthe instant invention could not withstand the centrifugal forces required to band viral particles in gradients. Conventional centrifuge tubes, or tubes derivative from the Sutherland design have been used for density gradient separations, and for separations in which wax or plastic barriers are used which position themselves between regions of different density to allow recovery of these fractions without mixing. There has been no previous discussion of barriers which prevent mixing of step gradient components at rest, but which barriers are centrifuged away from the gradient during rotation. Nor have tube closures for high-speed thin-walled swinging-bucket centrifuge tubes been described, whose exterior surfaces can be disinfected after the tubes are loaded. The efficient stabilization of very shallow density gradients in centrifugal fields is well known, and is utilized in analytical ulfracentrifugation to cause a sample layer to flow rapidly to the centripetal surface of a gradient without mixing using a synthetic boundary cell (Anderson, U.S. Patent No. 3,519,400). Hence, light physical barrier disks between step gradient components can be moved away from the gradient by centrifugal force without appreciably disturbing the gradient, provided that they are made of porous, woven or sintered materials having a physical density less than that ofthe sample layer, such as polyethylene or polypropylene.
Many authors have noted that viruses and bacteria are often resistant to the actions of detergents and enzymes which will digest or dissolve contaminating particles of biological origin, and efforts have been made to classify infectious agents on the basis of their differential sensitivities. These differences have not previously and conveniently been incorporated in a method for detecting and quantifying infectious agents. See, Gessler et al., 1956; Theiler, 1957; Epstein and Hold, 1958; Kovacs, 1962; Planterose et al., 1962; Gard and Maaloe, 1959. Density differences between different species of virus and bacteria are well known, but have not been previously exploited for purposes of identification. Infectious particles exhibit a wide range of isopycnic banding densities ranging from approximately 1.17 g/ml to 1.55 g/ml, depending on the type of nucleic acid present, and the ratios between the amount of nucleic acid, protein, carbohydrate, and lipid present. While such banding density differences are well known, no attempt has been previously made to systematically measure them and use the data to classify infectious agents. The present invention is directed to an integrated system for concentrating, detecting and characterizing infectious agents using separations based on sedimentation rate and banding density, spectral analysis of emitted fluorescent light to distinguish DNA from RNA, differentiation of viral and bacterial particles from other particles by sedimentation through zones of solubilizing enzymes or reagents, determination ofthe isopycnic banding densities of infectious particles by reference to the positions of synthetic density standardization particles, particle detection using fluorescent dyes for DNA or RNA, further concentration of banded particles by pelleting, transfer of concentrated particles to mass spectrometer targets for protein mass determination and analysis, counting of concentrated particles by epifluorescent microscopy and fluorescence flow cytometry, and identification of bacterial or viral nucleic acids by restriction fragment length polymorphism analysis using either immobilized nucleic acid molecules, or ultrasensitive fluorescence flow cytometry. These methods are especially useful in characterizing biological samples which have low titres of virus and which contain viruses which are not culturable.
Furthermore, all current methods used to detect and characterize infectious agents, including use of fluorescent antibodies, detection of agent-associated enzymes, culture to increase agent mass, PCR amplification, restriction fragment length polymorphism analysis, hybridization to probes immobilized on chips, histochemical analysis, and all forms of microscopy including electron microscopy, are vastly improved by preconcenfration ofthe microorganisms using the methods of the present invention.
The present invention is further directed to a method and apparatus for measuring light scatter from a microbanding zone.
These techniques have not previously been assembled into one operational system capable of routine field, hospital, and clinical laboratory use. The present application describes innovations and inventions which make such a system feasible. For work with potentially lethal agents, the system will be assembled in containment, and at least partially automated.
SUMMARY OF THE INVENTION The overall obj ective of this invention is to develop a physical system for rapidly identifying infectious disease agents without growing them, and for discovering new infectious agents. The process is based on the thesis that infectious agents constitute a unique group of particles which can be isolated by physical and chemical means from other natural particles and identified by their physical parameters using centrifugal means, light scatter, fluorescence, and mass spectrometry. The system will allow rapid clinical distinction between viral and bacterial infections, identification of specific agents with the aim of providing specific therapy, and the rapid discovery of new infectious agents. In addition the system will make it feasible to develop and test new antibiotics and antiviral agents in man by measuring the effects of these agents on bacterial and viral loads. At present the development of new antiviral drugs is severely hindered by inability to define populations of individuals in the early stages of infection who might benefit from treatment.
. In accordance with the present invention, an ultracentrifuge tube is provided which comprises upper, middle and lower regions of successively smaller diameters. In one embodiment, the tube has an upper region for receiving a sample, a funnel-shaped middle region and a lower narrow tubular microbanding region. The diameter ofthe lower region may be 0.25 inch or less, preferably 0.1 inch or less, more preferably 0.1 to 0.08 inch, and most preferably 0.08 to 0.039 inch. Smaller diameter microbanding regions are feasible and are within the province of this disclosure. The length ofthe lower region is typically between 5% to 25% of the length ofthe tube. In one aspect, the tube may also include a seal with a central opening which can be plugged and unplugged.
In accordance with the present invention, a bucket is provided for holding an ultracentrifuge tube. The bucket comprises upper and lower regions which may be of successively smaller diameters, may have inserts to successively decrease the inner diameter, or may be of uniform internal diameter, and may further comprise a third region which attaches the bucket to a rotor.
Further in accordance with the present invention, a method is provided for concentrating microorganisms. As used herein, the term "microorganisms" is intended to include viruses, mycoplasmas, rickertsia, yeast and bacteria. The method comprises ulfracentrifugation of a sample containing the microorganism in an ultracentrifuge tube described herein. The ulfracentrifugation may include the formation of density gradients and/or the staining ofthe microorganism(s). In one aspect, the staining can be used to distinguish the DNA or RNA content of a virus. The banding of the microorganisms upon ulfracentrifugation can be used to identify the microorganisms.
In a further aspect of the invention, the concentrated microorganisms are further characterized by conventional techniques such as mass spectrometry, flow cytometry, optical mapping, isopycnic banding densities, light scattering, fluorescence, restriction enzyme analysis, genome size, enzymatic or chemical resistance/susceptibility, immunochemistry and the like. In another aspect ofthe invention, the amount or titre ofthe microorganisms can be determined.
In accordance with the present invention, a system is provided for measuring light scatter and fluorescence from a sample in a centrifuge tube. In one embodiment, the system includes a centrifuge tube, a light source, such as a laser, and a detector to detect light passing through the sample or emitted or scattered from the sample upon light passing through it. Optical filters select and separate the exciting and emitted or scattered wavelengths of light. The internal surfaces ofthe tubes and especially the funnel portion must be very smooth in order to prevent small virus particles from being retarded by surface irregularities and, in addition, the surfaces must be treated so that infectious particles are not adsorbed. Polishing of plastic surfaces is done by brief exposure to a solvent vapor. For example, polycarbonate is polished by brief exposure to heated methylene chloride gas. Plastic surfaces are modified to prevent adsorption of infectious particles by exposure to dilute solutions of proteins such as bovine serum albumin or gelatin, or to charged polymers such as heparin or derivatives of heparin. Both of these procedures are well known to those practiced in the arts.
Further in accordance with the present invention, a system is provided for counting particles concentrated in a small volume. The system includes a container in which the particles are concentrated, a capillary tube, two pumps, means for moving the container relative to the capillary tube, a flow cell, a light source and detector. Alternatively, fluid may be moved by gas pressure instead of pumps.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows an S-rho plot for a typical tissue and for representative viruses. Figures 2A-2C are a diagrammatic representation of one embodiment of a centrifugal microbanding tube and its use.
Figures 3A-3G show alternative embodiments of microbanding tubes and use in a rotor (3F). Figures 4A and 4B illustrate a centrifuge swinging bucket design that allows higher speed fractionation of large sample volumes.
Figure 5 illustrates a complete system including vertical monochromatric laser illumination, goniometer and X-Y stage for supporting and positioning microbanding tube, microbanding tube with banded viruses particles, and camera system. Figure 6 illustrates a complete system including interference filter light sources, light pipe illumination, digital data acquisition, and CRT data presentation.
Figure 7 illustrates a method for recovering banded virus particles using a micropipette, and counting them by flow cytometry.
Figures 8A-8C illustrate details of band recovery. Figures 9A-9F illustrate one embodiment of a closure for swinging bucket rotor centrifuge tubes and detection of a sample with respect to the tubes. Figure 10 illustrates a complete system that is similar to the system depicted in Figure 5, the system in Figure 10 used to measure light scatter in accordance with the present invention.
Figure 11 is a computer generated graph indicating the intensity of measured light scatter from a microbanding zone in a centrifuge tube in accordance with the present invention. Figure 12 is an image from the camera ofthe system depicted in Figure 10 showing the light scatter from the microbanding zone in the centrifuge tube in accordance with the present invention.
Figure 13 is a computer generated graph indicating the intensity of measured fluorescence from the microbanding zone in the centrifuge tube in accordance with the present invention.
Figure 14 is an image from the camera of the system depicted in Figure 10 showing the fluorescence from the microbanding zone in the centrifuge tube in accordance with the present invention.
Figure 15 is a schematic drawing showing the system depicted in Figure 10, with elements removed to provide greater clarity and show the orientation ofthe polarized light from the laser in accordance with the present invention. Figure 16 is another schematic drawing showing the system depicted in Figure 10, with elements removed to provide greater clarity, and showing moveable filters that enable the system to measure both light scatter and fluorescence in accordance with the present invention.
DETAILED DESCRIPTION OF THE INVENTION The invention is directed to methods of identifying and measuring the presence of microbial agents such as bacteria and viruses in biological samples. The methods include centrifugation steps to purify the microbial agents in a very small volume. The agents are then assayed by means such as isopycnic banding density, light scatter detection, fluorescence or mass spectrometry.
It is an object of this invention to develop integrated systems and methods in which suspensions containing microorganisms, including infectious agents, are stained with one or more fluorescent dyes, in which a step or continuous gradient is automatically formed during centrifugation, in which the microorganisms are centrifuged away from the stain-containing suspending medium and are washed free of external stain, are concentrated in a gradient of very small cross section, separated according to their isopycnic banding densities, their banding densities determined, and the microorganisms detected by fluorescence.
It is a further object of this invention to concentrate microorganisms, including infectious agents, into microbands by a factor of 1-5,000. It is a further object of this invention to expose the microorganisms, such as infectious agents, to reagents including detergents, surfactants, enzymes, or organic solvents contained in distinct zones in a density gradient to dissolve or disassemble contaminating particles to prevent them from banding with the microorganisms, and to separate stained particles from the free stain ofthe initial sample volume.
It is a further object of this invention to use one or more dyes which bind differentially to RNA, single stranded DNA or double stranded DNA to allow these to be distinguished by their fluorescent spectra.
It is a further object of this invention to provide for the concentration of banded microorganisms, for example infectious agents, by resuspending the banding gradient, which is typically 0.04 mL, to approximately 4 mL in water or a very dilute buffer, and pelleting the microorganisms one or more times to provide a concentrated pellet free of gradient materials for mass spectrometric analysis, for counting by epifluorescent microscopy or by flow cytometry.
It is a further object of this invention to provide means for the diagnosis of infectious diseases which minimize exposure of laboratory personnel to infectious agents.
It is an additional object of this invention to provide means for preparing nucleic acids from small quantities of microorganisms, including infectious agents, to determine the masses of intact nucleic acid molecules, and for characterization of fragments produced by restriction enzymes using either flow cytometry or epifluorescence microscopy. It is an additional object of this invention to determine the banding densities of the microorganisms, such as infectious agents, accurately by reference to the positions of calibrated particles added to the gradients.
For ease of description, the invention will be described with reference to viruses as the microorganisms. It will be understood that the invention is also applicable to other microorganisms, including mycoplasmas, yeast and bacteria. The invention is particularly suited for the identification of infectious agents, and will be described in this context.
Figure 1 is a graph depicting the sedimentation coefficients and isopycnic banding densities of subcellular organelles and viruses to illustrate the concept ofthe "Virus Window" (Anderson, 1966). It is evident that viruses have a relatively narrow range of sedimentation coefficients and banding densities and may be isolated from a tissue homogenate or from blood in a high state of purity using high resolution S-p separation systems. For a complete description of high resolution S-p centrifugal methods and of centrifuge development for virus isolation, refer to National Cancer Institute Monograph 21, The Development of Zonal Centrifuges and Ancillary Systems for Tissue Fractionation and Analysis, U.S. Department of Health, Education and Welfare, Public Health Service, 1966. This work describes S-p separation theory and systems, and the use of colored plastic beads of graded densities as density markers. l In practice, a blood sample or tissue homogenate is centrifuged to sediment all particles having sedimentation rates higher than that ofthe particle or particles to be analyzed. For viruses, that means particles of circa 10,000 S and above are discarded. The supernatant after such a separation is then used as the sample for second dimension isopycnic banding separations carried out in microbanding tubes as described here, using centrifugation conditions which will sediment and isopycnically band all known infectious particles.
One picomole of virus would contain 6.022 x 10π viral particles, while 6 x 109 virions would contain 1 picomole of a viral coat protein present in 100 copies per virion. Quantitative polymerase chain reaction (PCR) has been used to demonstrate that in many infectious diseases > 108 virus particles are present per mL of plasma or serum. Hence, if the virions from a 5-10 mL biological sample containing 108 virions/mL are concentrated to a microliter or two, and then applied to a very small target area, individual viral proteins can be detected using MALDI-TOF-MS (Krislimanurthy et al., 1996; Holland et al., 1996). Using electrospray techniques, samples containing 106 virus particles/mL can be detected, while with flow cytometry and immobilized DNA epifluorescence microscopy, even fewer particles are required (Hara et al., 1991; Hennes and Suttle 1995). The application of these methods to bacteria may require a preseparation of proteins to reduce the complexity ofthe sample. In mass spectrometry, detection has been by charged ion detection, and the limitations of such detection have set the upper limits to the size of proteins and nucleic acids that can be detected. Mass spectrometric methods have now been described which allow masses of biological particles above 100,000 daltons to be measured. In order to work with such levels of virus, the virus must be concentrated into a very small volume. This concentration is accomplished during the second dimension of centrifugation (the isopycnic banding step) by banding the virus using a centrifuge tube specially designed to concentrate the virus into a microband after passage through gradient layers that wash the particles and expose them to selected reagents. An example of such a microbanding centrifuge tube is shown in Figures 2A-2C. Figure 2A illustrates diagrammatically a hollow transparent centrifuge tube 1 with an upper sample volume 2, grading into a serrated funnel region 3 having successively tapered and parallel-wall sections 4-6, constricting down to a narrow tubular microbanding region 7. The serrated funnel region 3 is an improvement over centrifuge tubes which simply taper from top to bottom without including a serrated region. By serrations is meant, for example, concentric rings or edges or lips. These rings, edges or lips are preferably continuous around the inner diameter of the centrifuge tube, but this is not required. For example, three projections from the inner wall of the centrifuge tube spaced equally around the diameter could be used to hold a disk in place. The term serrations is meant to include such possibilities but does not include a straight tapering with no rings, edges, lips or projections on the inner surface ofthe centrifuge tube. The serrations can be used as rests onto which disks can be placed to separate two or more layers of liquid. Although disks can be placed into tubes which simply taper without serrations, the disks in such tapered tubes can be easily tipped up on one edge by pushing down on the opposing edge. This would cause a premature mixing ofthe layers which are to be separated by the disks. The serrated region allows disks to lie flat and prevents the disks from being accidentally tipped up. As an example, the centrifuge tube may be 3.45 inches from top to bottom, have an outer diameter at the top of 0.562 inch, and have an inner diameter in the bottom microbanding region 7 of 0.064 inch. Such a tube is suitable for use in an SW41 Ti (Beckman) rotor. The inside surface of the tube is preferably polished using conventional techniques, including vapor polishing, so that the virus particles do not stick to the wall ofthe tube. Additionally, the internal surfaces ofthe tubes may be coated with a protein or polymer to prevent particle adhesion, as is well known in the art.
Figure 2B illustrates how the tube is loaded at rest with a series of fluids of decreasing physical density. The tube shown comprises a series of serrations onto which can be laid disks to separate one layer of fluid from the next layer of fluid. Liquid 8 is denser than any particle to be recovered, and is used to partially fill the microbanding region 7. When a less dense fluid 9 is pipetted in with a micropipet an air bubble 10 (wherein by air is meant atmospheric air or another gas) may be left to keep the fluids 8 and 9 separate. Similarly when the first overlay fluid 11 is introduced, air bubble 12 may be left in place, thus keeping the three liquids separate until centrifugation is commenced. A tube with an inner diameter of 0.064 inches in microbanding region 7 is suitable for allowing an air bubble to be left in place to separate two layers of liquid. Alternatively, the air bubbles may be left out and the fluids allowed to diffuse together to create a density gradient. Fluid 11 is covered with a light porous plastic disk 13, preferably of sintered polyethylene or polypropylene, which fits in place in the first serration. A fluid 14, less dense than fluid 11, which may contain one or more reagents, is then introduced, and covered with disk 15, followed by even less dense liquid 16 which is covered with disk 17. The entire system is stable until centrifuged. Before use the sample layer 18, which has a density less than that of fluid 16 is then added up to level 19. The tubes are then centrifuged at high speed in metal shields, typically with water or other liquid added to the shields. In addition, the tubes may be supported by fitting adapters which fill the space between the tubes and the shields, and water may be added to fill any spaces between the tubes, adapters and shields to provide additional support. Optionally the tubes may be capped (as shown in Figures 9A-9F, described in further detail below), to minimize the chances of operator infection.
Figure 2C illustrates diagrammatically a tube after centrifugation. The porous separation disks 13, 15, and 17 have risen to the top ofthe tube, and sample layer 18 is cleared of virus, and the original step gradient has changed, by diffusion, into one of a series of shallow gradients. In addition, gas bubbles 10 and 12 have also moved centripetally, and fluids 8 and 9 have come into contact to form a steep gradient by diffusion. As centrifugation proceeds, the slope of this gradient diminishes, producing a banding gradient of a width suitable for banding the infectious agents. For cesium chloride gradients, the densities typically range from 1.18 to 1.55 g/ml. These gradient steps may not only contain reagents to dissolve non- viral particles, but also serve to wash excess fluorescent dye away from the particles. For example, various detergents or enzymes such as proteases may be added either to the sample layer 18 or to other layers such as 14 or 16. Fluorescent dyes may also be present in these regions. The free dye will not enter the lower, more dense regions in which the virus bands and therefore the centrifugation will purify the viruses from all of the reagents which may be present in the upper, less dense layers. After centrifugation, the microbanding region ofthe tube contains the upper portion ofthe banding gradient 27, banded virus 28 (including any dye bound to the virus or viral nucleic acid) and lower dense portion of the banding gradient 29, and the gradient formed between them by diffusion.
Figures 3A-3G illustrate alternative embodiments of tubes useful for microbanding of viruses and bacteria and all have a serrated internal construction which allows one or more light barriers to be positioned and retained at rest. Tubes shown in Figures 3A-3D and 3G are designed to be centrifuged in swinging bucket rotors so that the tubes are horizontal during centrifugation and vertical at rest. The tube shown in Figure 3A is the more conventional design with a sample reservoir 31, a serrated funnel region 32, and a microbanding section 33. The tube shown in Figure 3B is similar to that of Figure 3 A, but it is supported in a centrifuge shield by a support insert 34 which may be of plastic or metal. The tubes shown in Figures 3B-3E fill a rotor chamber completely. The tube of Figure 3C has an opaque bottom section 35 which absorbs scattered light, while that shown in Figure 3D has a bulbous section 36 at the bottom ofthe microbanding tube 37 to contain an excess volume ofthe fluid forming the dense end ofthe gradient, thus stabilizing the gradient. The tube shown in Figure 3E is designed to be centrifuged in an angle head rotor as shown in Figure 3F, and has a linearly continuous wall 38 along one side positioned in the rotor so that particles may readily slide down to microbanding region 40. The tube shown in Figure 3G illustrates how a very large microbanding tube may be fabricated.
Figures 4A-4B illustrate how the tube of Figure 3G may be centrifuged at higher speed than tubes having a constant radius from top to curved bottom. This is accomplished by using a metal, plastic or carbon fiber shield 45 which matches the dimensions of tube 46. The shield has a cap 47 and the shield or bucket swings on integral attachment 48, as is conventionally done in high speed swinging bucket rotors. Tip 49 ofthe shield is much smaller diameter than the upper section ofthe shield, has much less mass swinging at its maximum radius, and hence can reach much higher speeds than is the case with shields of uniform internal diameter. This makes possible isolation of trace amounts of virus from much larger volumes than would otherwise be the case. During centrifugation using rotor 50 driven by drive 51, shield and tube 52 assume a horizontal position as shown.
The microbanded viruses can be analyzed at this stage or they can be collected, diluted, and further processed. To analyze the microbanded viruses at this stage, they can be detected by a system as shown in Figure 5. For example, the isopycnic banding step or an earlier step may have included a fluorescent dye or fluorescent dyes within the solution with which the virus was mixed or through which the virus was centrifuged. Dyes are known with which intact viruses may be stained and which can distinguish between RNA, DNA, single stranded nucleic acid and double stranded nucleic acid thereby allowing one to detect the presence or absence of an infectious agent, and further to determine which type of virus one has purified. The apparatus of Figure 5 can be used to analyze these stained particles.
A scanning and detection system is illustrated schematically in Figure 5 where microbanding tube 60 is held in a vertical position on mount 61 supported by goniometers 62 and 63 which are in turn supported by X-Y movements 64 and 65 in such a manner as to align and center the microbanding section of tube 60 with respect to laser beam 66. Laser beam 66 is generated by a laser 67, which may be an argon ion laser producing coherent light at 458, 488, 496, 502, and 515 nm. The beam passes through an interference or other filter 68 to isolate one wavelength, and is reflected down into the microbanding tube by dichroic mirror 69. The fluorescent banded particle zone 70 is photographed or electronically scanned by camera 71 through emission filter 72. The entire system may be enclosed to eliminate stray light, and filters 68 and 72 may be replaced by filter wheels (not shown) to optimize detection using fluorescent dyes which absorb and emit at different wavelengths, or to distinguish ssDNA, dsDNA and RNA by differences in the spectra of emitted fluorescent light. Electronic shutters may be attached to the laser to minimize sample exposure to light and to the camera to control exposure. The goniometers and X-Y movements may also be motor driven and remotely controlled, and the entire system may be controlled by a computer (not shown).
Figure 6 illustrates a different version of the scanning system which can cover all of the visible spectrum and on into the near ultraviolet. Microbanding tube 80 is aligned in a fixed support between transparent intensity equihbrators 81 and 82 attached to light pipes 83 and 84 which are in turn attached to intensity equilibrator 85 illuminated through filter 86 by condensing lens 87 and - light source 88. Filter 86 is one of a set attached to filter wheel 89 indexed by motor 90. The result is uniform illumination from two sides of one or more bands 91, 92 and 93. The image is captured through emission filter 94 by digital camera 95 and the image stored, processed and displayed by computer 96 on CRT 97. Filter 94 may be replaced by a filter wheel identical to 89 and 90 so that, with both an excitation filter wheel and an emission filter wheel and a wide spectrum light source such as a xenon lamp or a halogen lamp, a wide variety of combination of exciting and emitting light may be chosen, which in turn makes possible use of a wide variety of fluorescent dyes. Both fluorescent light and light scatter at a chosen wavelength may be employed for particle detection.
This arrangement facilitates distinction between ssDNA, dsDNA and RNA.
The processed image 98 may be displayed to show a picture ofthe tube and contained bands 99, 100 and 101. The amount of light from each band may be integrated and displayed as peaks 102, 103, and 104, and in addition the integrated values may be displayed digitally (not shown). The entire system including shutters on the light source and camera (not shown), filter movement and positioning, and focusing ofthe camera may be digitally controlled by computer 96.
Display bands 99 and 101, representing centrifuge tube bands 91 and 93 may be fluorescent or non-fluorescent density marker beads of known density, and the virus band 92 represented by display band 103. The banding density ofthe virus may be determined by interpolation from the positions ofthe density markers. When non-fluorescent density markers are used, these are detected by scattered light using identical filters at positions 86 and 94. A second image using suitable and different filters is then captured which is comprised solely of fluorescent light. The two images are electronically inter-compared and the physical density of the infectious agent determined by interpolation.
At this stage, the virus can be identified as being a DNA virus or an RNA virus, and if a
DNA virus it can be determined whether it is single stranded or double stranded. Furthermore, the density of the virus can be determined. This data can be used to help identify the type of virus which has been purified. Nevertheless, it may be desirable or necessary to gather more data to fully determine what the exact virus is and also to determine the original viral titre.
Figure 7 illustrates diagrammatically counting of individual fluorescent particles recovered from a tube 110 containing zones of banded virus 111 and 112 after all fluid above the banding gradient has been removed and replaced. The tube is placed in a tube holder 113, and an overlay of deionized water or very dilute buffer 114 is introduced above the gradient supplied through tube 115 to replace the volume drawn up in the probe 117. The tube may be closed at the top by a plastic closure 116. The capillary probe 117 is held stationary, and the microbanding tube 110 is slowly raised under it. The tube holder 113 is part of a precision drive mechanism 118 and associated stepping motor 119 that moves the tube holder vertically at a very slow and controllable rate. A slow steady stream of fluid is drawn into constriction 120 which is centered in sheath stream 121 provided by pump 122. The result is a constant flow of fluid through flow cell 123 with a fine virus containing stream in the center, elongated and extended by the flowing sheath. A second pump 124 withdraws fluid upward at a constant rate from the flow cell, which rate is greater than the rate at which piston pump 122 injects fluid into sheath 121. The difference in the rates of pumps 124 and
122 is made up by the fluid coming through capillary probe 117. The fluid coming through capillary probe 117 is a mixture of virus plus fluid from the overlay which is introduced via tube 115.
The flow cell 123 is illuminated by laser beam 125 produced by laser 126, that passes through exciting filter 127. Emitted light is isolated by emission filter 128 and detected by a photomultipher 129. The output from the photomultipher 129 is integrated at intervals by computer 130, and the integrated signal vs. time is displayed on CRT 131. When two viral bands are present, two peaks such as 132 and 133, are displayed. Depending on the number of fluorescent particles present, the signal generated from a band may be integrated into a peak, or, if the suspension is sufficiently dilute, the particles may be counted individually, the values binned, and the integrated results displayed. In order to count the particles as just described, it is necessary that the virus particles are greatly diluted as they pass through flow cell 123. Figure 8 illustrates diagrammatically how the problem of making an initial dilution of a very small-volume virus band for counting individual particles is accomplished. Figure 8 A shows a tube 110 as in Figure 7, with a section indicated which is shown enlarged in Figure 8B, which in turn shows the section of that panel enlarged in
Figure 8C. As the movement upward ofthe microbanding tube causes the capillary tube to move toward the tube bottom, the difference in pumping rates ofthe two pistons attached to the flow cell causes fluid to flow up the capillary where it is diluted as described by the combined action of pumps 122 and 124 of Figure 7. However, the amount of fluid drawn into the capillary 117 is much greater than the volume of fluid effectively displaced from the banding gradient by the relative movements ofthe capillary and the microbanding tube. This volume is replaced by fluid flowing into tube 115 though cap 116 which is initially allowed to flow in until the tube 110 is full. This fluid is much less dense than the density ofthe fluid at the top ofthe gradient in the microbanding region, and causes minimal disturbance in the gradient. As shown in Figure 8B, the capillary 117 slowly approaches virus band 144, and, as shown in Figure 8C, a small amount of gradient liquid
145 is diluted by a larger amount of supernatant fluid 114 as it flows up the capillary. In this manner, a sharp band of virus particles 144 is diluted and moves through the flow cell as, volumetrically, a larger band, but with little effective loss of resolution. This technique provides the dilution necessary to make counting of individual virus particles feasible and accurate. The amount of dilution can be controlled such that the concentration of microorganisms in the capillary tube is less than one-half or one-tenth, or one-hundredth, or one-thousandth, or one ten-thousandth, or one-millionth, or one-billionth ofthe concentration in the band in the lower region of said tube.
In addition to counting the particles or determining the titre of a virus, the amount of DNA in the virus or other microbe can be determined for individual particles. In this aspect of the invention, the amount of DNA in the particles is measured by flow fluorescence analysis (Goodwin et al., 1993) or epifluorescence analysis (Jing et al., 1998). In this manner, yeast, bacteria, mycoplasma and virus can be distinguished as groups, For example, it is known that viruses contain 5-200 x 103 bases or base pairs, E. coli, a typical bacterium, contains 4 x 106 base pairs, while a typical yeast cell contains 1.3 x 107 base pairs. Thus, an estimate ofthe amount of DNA or RNA present allows the class of an infectious agent to be determined.
Thus, the size of a genome can be determined. In this embodiment of the invention, the genome is extracted from the microorganism band and immobilized on a solid support. The immobilized DNA is stained and electronically imaged using an epifluorescence microscope (Jing et al., 1998). The length ofthe individual nucleic acid molecules can then be measured.
The technique of microbanding is useful not merely for staining the virus with dyes and being able to count the virus particles. Once the viruses from a biological sample have been highly purified and concentrated by the two dimensional centrifugation technique as described above using microbanding centrifuge tubes, the viruses are amenable for use in many other assays.
When an infectious agent is banded in a microbanding tube, the band may also be judiciously removed using a capillary needle in a volume of a few micro liters, diluted to 5 mL or more with very dilute buffer or deionized water to dilute the gradient materials by a factor as large as 1,000, and then pelleted in a fresh microbanding tube. The supernatant may then be carefully withdrawn by a suction capillary, and the virus or other agent resuspended in approximately 1 microliter using a syringe made, for example, of fine Teflon® tubing fitted with a very small stainless steel wire plunger to fit. The sample may then be transferred to a mass spectrometer target, mixed with a matrix dye, and used for matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) to determine directly the masses of viral coat proteins or of bacterial cell proteins. Technology described for sample concentration may also be applied, without a matrix dye, to electrospray or other mass spectrometric analysis systems, including the detection of intact viral mass.
A system similar to that shown in Figure 7 may also be used to produce the equivalent of molecular restriction fragment length maps of DNA molecules using restriction enzymes. For this work, virus or bacterial particle bands may be diluted and sedimented as described, after which the DNA may be extracted using detergents or other reagents well known in the art, treated with a restriction enzyme and a fluorescent dye, and the fragment sizes determined by flow cytometry (Goodwin et al., 1993; Hammond et al, U.S. Patent No. 5,558,998). Extracted DNA may also be immobilized on a solid support, stained with a fluorescent dye, and photographed using an epifluorescence microscope to determine the length of DNA molecules. The preparation may then be treated with a restriction endonuclease, and the number and lengths of the oligonucleotide fragments determined (Jing et al., 1998). These data are then compared with a database listing the expected fragment lengths for different viral or bacterial species to identify each agent. DNA fragment lengths may also be determined by gel electrophoresis.
Fluorescence labeled antibodies may also be added to the particle suspension studied, and the presence or absence ofthe label in isopycnically banded particles determined. This approach is useful for specific identifications, and the use of a set of antibodies labeled with dyes having different and unique spectral characteristics allows the presence or absence of a series of agents to be determined. Alternatively antibodies labeled with chelators for rare earth's such as Europium and Terbium may be employed, in which case delayed fluorescence is measured. Serum or plasma typically has a physical density between 1.026 and 1.031. Viruses typically have banding densities between 1.17 and 1.55 in cesium chloride, and at much lower densities in iodinated gradient materials such as lodixanol or sucrose (Graham et al., 1994). The intermediate wash and reagent layers between the sample and the banding gradient must therefore have densities less than the density ofthe lightest virus to be banded. Buffers used to dissolve gradient material for virus isolation include 0.05 M sodium borate, and 0.02 M sodium cyanide, both of which prevent bacterial growth.
With human serum or plasma, centrifugation sufficient to remove platelets and other particles having sedimentation coefficients of approximately 104 S is used before banding of virus particles. The banding density of virus particles depends on the nucleic acid/protein ratio, and the presence or absence of lipids and lipoproteins. Hence attachment of specific identifying antibodies labeled with fluorescent dyes should not only allow identification by fluorescence but by a banding density change.
To assist in identifying particles by density, fluorescent particles of known density may be included in the sample as shown in Figure 6. These particles may include known fixed and fluorescently stained virus or bacterial particles of known banding density, or very small fluorescently labeled or non-fluorescently labeled plastic beads. When polystyrene latex particles are coated with antibodies, their banding densities are increased appreciably, and the density may be further increased by reaction of the antibody-coated particles with the antigen for which the antibodies are specific (Anderson and Breillatt, 1971). Antibody-coated fluorescent polystyrene beads may therefore be used not only to locate virus particles but to identify them.
The stains which are currently most useful are described in the Handbook of Fluorescent Probes and Research Chemicals, R.P. Haugland, ed., Molecular Probes, Inc., Eugene, Oregon (1996), which lists the abbreviated dye names, their chemical names, absorption and emission maxima, and the filter combinations most used.
For work with human pathogens, safe operation and containment are important (Cho et al., 1966). Use of swinging bucket rotors, while optimal from a physico-chemical point of view, require extensive manipulation and have more parts than an angle-head rotor. The tubes described in Figure 3E are designed to be used in angle-head rotors, and allow sedimenting particles to travel along a wall at one unchanging angle. Such rotors are easier to use and handle in containment than are swinging bucket rotors, however, sedimentation in an angle head rotor is far from ideal. Hence, the development of methods and devices for safely working with swinging bucket rotors is important.
High speed centrifuge tubes are notoriously difficult to seal effectively and are a potential source of infection to laboratory personnel. In practice, nearly all high speed swinging bucket rotor tubes are not themselves sealed, but are enclosed in a metal bucket which is sealed with a metal cap which does not seal the tube. The centrifuge tubes are therefore open when loaded, moved to the centrifuge rotor, inserted, and removed. It is very difficult to decontaminate the outside of an open tube containing a density gradient without disturbing the gradient. In the present application it is desirable to be able to effectively seal the plastic tubes is such a manner that the outside surfaces can be cleaned with a suitable disinfectant before the tubes are inserted into centrifuge shields, and to be able to handle them safely until they are scanned. Sealing is done, as shown in Figure 9A, by inserting an annular ring seal 151, having a physical density less than that of water, into tube 152. Ring 151 is slightly tapered so that it fits very tightly into tube 152, and has a center hole which can be plugged and unplugged. In one embodiment, the center hole is threaded to accept a short, plastic flat-head screw. Initially two gradient components, including a lighter solution 153 and a denser solution 155, are introduced to the bottom microbanding region with a small air bubble 154 between, as previously described. As shown in Figure 9B, the solution 156 containing the infectious agent or other particles is then introduced through tube 157, leaving bubble 158 to separate the sample from the upper gradient solution. The volume of sample introduced does not completely fill the centrifuge tube, leaving space 159 empty. The tube is then sealed, as shown in Figure 9C with, for example, a plastic flat head screw 160, leaving air bubble 160 in place. The outside of the tube is then sterilized by immersing it in a disinfectant such as a sodium hypochlorite or hydrogen peroxide solution, followed by a water wash and gentle drying - all with the tube in an upright position. After centrifugation, as shown in Figure 9D, the plastic upper seal has been driven downward by centrifugal force a small distance as the entrapped air rises around the plastic seal. However, since the seal has a density less than water, it is retained at the top ofthe liquid sample, leaving a small lip 160 which may be grasped with a hemostat to remove the tube from the centrifuge shield. During centrifugation, the infectious particles are sedimented out of liquid 163 and produce band 164 in the gradient. The screw in the ring seal is then removed, and, as shown in Figure 9E, the supernatant liquid 165, which may contain a fluorescent dye, is removed through tube 166, leaving meniscus 167. As shown in Figure 9F, a laser beam 168, entering the tube from above, is then aligned with the tube, causing the banded infectious agent to emit fluorescent light for detection as previously described.
When a step gradient containing various reagents in addition to those used for isopycnic banding is employed, as illustrated in Figure 2, the discs used to separate the several solutions rise to the top and would not allow the use of vertical laser illumination as shown in Figure 9F without removing the seal and the discs, h this instance, side illumination, as illustrated in Figure 6 would be employed.
The laser or delayed fluorescence systems can be completely contained, the mechanical operations done remotely through small stepping motors, and the tubes moved in and out of the contained system under remote control.
These techniques can be combined with mass spectrometry and fluorescence-based restriction fragment mapping to allow rapid diagnosis and identification of infectious agents.
However, the estimates of the masses of individual proteins are generally taken from published sequence data, and do not include numerous posttranslational modifications. Mass spectrometric data bases must be created to include actual mass measurements of different microorganisms. In addition, virion protein mass measurements will allow the detection of many genetic variants. However, for many studies of microorganisms, including development of data bases, the key problem has been the development of methods for systematically providing highly concentrated and purified microsamples of microorganisms from patient samples, natural waters, and from tissue culture fluids. This problem is solved by the present invention.
An alternate embodiment of a virus detecting system, depicted in Figure 10, is configured to detect viruses without the use of a dye, such as the fluorescent dyes mentioned above with respect to the system depicted in Figure 5. The virus detecting system depicted in Figure 10 includes many ofthe components ofthe system in Figure 5, but instead of detecting fluorescence from a fluorescent dye, the system in Figure 10 measures scattered light emitted from the microbanded viruses.
The scanning and detection system illustrated schematically in Figure 10 includes a mount 61 that supports a microbanding tube 60 in a vertical position. The mount 61 is supported by goniometers 62 and 63 which are in turn supported by X-Y movements 64 and 65 in such a manner as to align and center the microbanding section of tube 60 with respect to a laser beam 66. Specifically, the X-Y movements 64 and 65 are for orthogonal adjustments in a horizontal plane. The goniometers 62 and 63 are each adjustable about perpendicular conical surfaces that have center lines that pass though a portion ofthe tube 60. By adjusting the positions ofthe goniometers 62 and 63 and X-Y movements 64 and 65 it is possible to align the particle zone 70 with the laser beam 66. The laser beam 66 is generated by a laser 67, which may be an argon ion laser producing, for instance, coherent light at 458, 488, 496, 502, and 515 nm. One such laser producing device is the Omnichrome 5025 which is an argon laser. Some lasers include internal filters or other internal wavelength determining means such that only a selected wavelength of light is emitted from the laser. For such lasers, no external filter is necessary for producing coherent light at a single frequency, although external filters may be used if desired or if necessary for using a different laser light source. For the configuration ofthe present invention depicted in Figure 10, polarized light is desirable and therefore the laser beam 66 may alternatively be provided by any laser light source that produces polarized light at a single frequency. The inventor has determined that smaller wavelengths are more advantageous in the light scattering measurement ofthe present invention. Specifically, a frequency of polarized laser light at 488 nm produces optimal results, as is explained in greater detail below.
The laser beam 66 is reflected down into the microbanding tube 60 by dichroic mirror 69. A banded particle zone 70 is photographed or electronically scanned by camera 71 without the need of a filter. The entire system may be enclosed to eliminate stray light. A camera 71 focused on the banded particle zone 70 measures the light scattered therefrom due to the laser beam 66 trained on the particle zone 70.
Planar polarized light, such as the laser light produced by the laser 67, includes a magnetic component H and an electric component E that are perpendicular to one another. Specifically, for planar polarized light, the electric component E travels in a plane that is perpendicular to the magnetic component H. The orientation of the laser beam 66 is such that as the laser beam 66 passes through the banded particle zone 70, the plane defined by the electric component E is normal (perpendicular) to the line of sight from the camera 71, as is shown in Figure 15. Note that Figure 15 does not include the tube 60 in order to provide greater clarity, but does show the banded zone 70. The inventor has discovered that with the laser beam in the above described orientation, shown in Figure 15, greater sensitivity is achieved in the measurement of scattered light emitting from the banded zone 70 compared to measurement of fluorescence emitted from dyes that may be in the banded zone 70.
The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.
Example 1 To illustrate the use of microbanding tubes, experimental studies have been carried out using a small single-stranded non-pathogenic DNA virus φX 174. Approximately 1010 virus particles which had been purified by isopycnic banding in CsCl in a microbanding tube such as shown in
Figure 2A were suspended in 5 mL of 0.05 M borate buffer, were pelleted in a microbanding tube at 35,000 rpm in a swinging bucket rotor, and were resuspended in approximately 3 μL for analysis. The analyses were done on a PerSeptive Biosystems DESTR instrument with an extraction delay time set at 150 nseconds using a matrix of sinapinic acid. Bovine insulin (MW=5,734.59) and horse heart apomyoglobin (MW=16,952) were used as 1 and 2 pmole standards. The results are shown in Table 1. The φX 174 masses for virion capsid proteins F, G, H and J are calculated from published sequence data. The differences between the calculated and experimental values for F and H are probably due to posttranslational modifications. The probability that an unrelated virus could have subunits ofthe same masses listed is vanishingly small. However, even more definitive protein identifications can be made by treating viral proteins with proteolytic enzymes such as trypsin and determining the masses ofthe peptide fragments produced. Computer programs are available which calculate the sizes of fragments of proteins of known sequence by well characterized enzymes. Such programs include Protein Prospector (available from the University of California, San Francisco) and ProFound (available from Rockefeller University).
Table 1
Mass Spectrometric Analysis of φX 174 Virion Proteins
Protein Calculated Mass Experimental Mass Mass Difference % Difference
F 48,351.53 48,407.4 +55.9 0.12 % G 19,046.73 19,046.7 0.0 0.00 %
H 34,419.25 34,466.1 +46.9 0.14 %
J 4,095.78 4,097.03 +1.2 0.03% This example demonstrates that highly purified and concentrated suspensions of microorganisms can be isolated from biological samples such as, but not limited to, patient samples such as plasma, urine, feces and tissues, natural water and tissue culture fluids. This example further demonstrates that such purified and concentrated microorganisms can then be identified, for example, using mass spectrometry to identify viruses.
Example 2 The inventor conducted an experiment to demonstrate the greater sensitivity realized by measuring scattered light with the camera 71 focused on a zone 70 with the line of sight of the camera 71 being normal to the plane ofthe electric component E ofthe laser beam 66. Specifically, lambda phage was purified by banding in cesium chloride and diluted to a titer of 1.5 x 1010 plaque forming units per mL. 1.5 mL of this preparation was mixed with 25 μL of 1 mM YOYO-1 fluorescent DNA stain (marketed by Molecular Probes, IN), and left at refrigerator temperature for three days. Parallel sets of microbanding tubes were set up with a step gradient set up in the microbanding region using 17 μL of room temperature saturated cesium chloride at the bottom, followed by 17 μL of a 1 :10 dilution ofthe saturated solution in phosphate buffered saline (PBS), pH 7.2. This in turn was followed by 1.5 mL of 1 :20 dilution ofthe same saturated solution in PBS. These solutions were then spaced with small air bubbles, a process made feasible by the very small diameter ofthe microbanding region ofthe tubes 60. Two parallel sets of tubes 60 were then filled, one set with PBS containing 3 x 108 stained virions, and the other set with PBS containing 3 x 108 unstained virions. All ofthe tubes were then centrifuged for 3 hours at 40,000 rpm in an SW41-Ti rotor in a Beckman L-70K ultracentrifuge. The tubes were vertically illuminated with polarized laser light at 488 nm using an argon ion laser. Images were captured using an Apogee CCD camera. Scatter was measured with both the dyed and non-dyed virus using 488 nm light, while the light emitted by the stained virus was measured using 510 nm light using an interference filter.
Figure 12 shows the scatter image generated by the camera 71 of one microbanding zone 70, while Figure 14 shows the fluorescence image generated by the camera 71 of the same microbanding zone 70. Figure 11 shows a computer generated graph ofthe light intensity detected by the camera 71 based upon the image in Figure 12, and Figure 13 shows a computer generated graph ofthe fluorescent light intensity based upon the image in Figure 14. The intensity units (the numbers on the vertical axis) on the graphs in Figures 11 and 13 are the same. However, the depicted graphs were automatically scaled by the computer to fit a predetermined portion of the computer monitor. As can be seen by comparing the graphs in Figures 11 and 13, the peak height ofthe line scan for scatter was approximately 2300 arbitrary intensity units, while the peak height for the fluorescent virus was only 540 arbitrary intensity units. Clearly, detection of scatter is more sensitive than detection fluorescence under the conditions employed.
An advantage of light scatter measurement is that it is possible to determine the particle size by measuring the angle of maximum light scatter. Therefore, more information is obtainable from measurement of light scatter than from measurement of fluorescence. Further, some fluorescent dyes degrade after exposure to laser light. Light scatter is not affected by duration of exposure to laser light.
The inventor has further determined that the shorter the wavelength of light from the laser 67, the greater the amount of scattered light resulting in an increase in sensitivity. Specifically, several ofthe frequencies of polarized light produced by the laser 67 were used, one frequency at a time, in order to measure light scatter from a single microbanding zone 70. A polarized beam of light of 488 nm yielded the best results.
It is also possible to measure both fluorescence and light scatter on the zone 70 by using the camera 71 and moving at least filter 72 into position as indicated by the arrows in Figure 16. Note that the filter 68 is depicted, but is only necessary if the laser 67 outputs several wavelengths of light. The line of sight of the camera 71 is normal (perpendicular) to the plane with the electric component E. The camera 71 is first used to measure quantitatively the light intensity of light scatter from the zone 70 without the filter 72. The filter 68 is required to allow only one frequency of light if the laser 67 outputs several frequencies of light. Thereafter, the filter 72 is moved into position in front of the camera 71 and fluorescence is measured to confirm that the particles are viruses and not, for instance, dust, dirt or other non-essential components. It should be understood that fluorescence measurement is not dependent upon the orientation of polarized light because the fluorescence emitted by the dye is excited by the laser light to emit light and does not necessarily reflect the laser light.
By the above described method and apparatus it is possible to obtain information from a single zone 70 by measuring both light scatter and fluorescence. Another aspect of the invention is the addition of a polymerizable material, such as acrylamide, in the lower portion ofthe tube 60 that is hardened after centrifugation such that the banded virus may be fixed in position within the tube 60 for later excising and analysis. For instance, sodium alginate may be introduced into the tube 60 and, after centrifuging, calcium ions may be added to the surface causing the mixture in the tube 60 to gel. The semisolid mass in the tube can be removed, and the zone with the virus removed for further study.
The above described methods and apparatus can be used to detect or isolate viruses from plants, animals or environmental sources.
While the invention has been disclosed in this patent application by reference to the details of preferred embodiments ofthe invention, it is to be understood that the disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit ofthe invention and the scope of the appended claims.
LIST OF REFERENCES
Anderson, N.G., ed. (1966). "The Development of Zonal Centrifuges." Nat/. Cancer Inst. Monogr. 21.
Anderson, Ν.G. et al. (1966). "Separation of subcellular components and viruses by combined rate- and isopycnic-zonal centrifugation." In The Development of Zonal Centrifuges. Ν.G. Anderson, ed. National Cancer Institute Monograph 21: 253-284.
Anderson, Ν.G. et al. (1967). "Isolation of viral particles from large fluid volumes." In Transmission of Viruses by the Water Route. G. Berg ed., Interscience Publishers, Y, pp. 75-88.
Anderson, Ν.G. (1968). "Analytical techniques for cell fractions. VIII. Analytical differential centrifugation in angle-head rotors." Anal. Biochem. 23: 72-83.
Anderson, Ν.G. and Breillatt, J.P. (1971). "Isopycnometric serology: A new technique based on buoyant density changes in latex beads." Nature 231: 112-114.
Bergh, O. et al. (1989). "High abundance of viruses found in aquatic environments." Nature 340: 467-468.
Borsheim, K.Y. et al. (1990). "Enumeration and biomass estimation of planktonic bacteria and viruses by transmission electron microscopy." Applied Environ. Microbiol. 56: 352-356.
Chang, Y. et al. (1994). "Identification of herpes virus-like DΝA sequences in AJDS-associated Kaposi's sarcoma." Science 265: 1865-1869.
Cl o, Ν. et al. (1966). "Problems in biocontainment." Nat/. Cancer Inst. Monogr. 21: 485-502.
Claydon, M.A. et al. (1996). "The rapid identification of intact microorganisms using mass spectrometry." Nature Biotechnology 14: 1584-1586.
Fenselau, C. (ed.) (1994). "Mass spectrometry for the characterization of micro-organisms." ACS Symposium Series, Vol. 541, ACS, Washington DC.
Fredricks, D.M. and Relman, D.A. (1996). "Sequence-based evidence of microbial disease causation: When Koch's postulates don't fit." J. NIHRes. 8: 39-44.
Gao, S.-J. and Moore, P.S. (1996). "Molecular approaches to the identification of unculturable infectious agents." Emerging Infectious Diseases 2: 159-167.
Goodwin, P.M. et al. (1993). "Rapid sizing of individual fluorescently stained DΝA fragments by flow cytometry." Nucl. Acids Res. 21: 803-806.
Graham, J. et al. (1994). "The preparation of subcellular organelles from mouse liver in self- generated gradients of lodixanol." Anal. Biochem. 220: 367-373.
Hara, S. et al. (1991). "Abundance of viruses in marine waters: Assessment by epifluorescence and transmission electron microscopy." Applied Environ. Microbiol. 57: 2731-1734.
Harris, W.W. et al. (1966). "Unusual particles in human plasma from leukemia and lymphosarcoma." In The Development of Zonal Centrifuges. National Cancer Institute Monograph 21: 289-394. Haugland, R.P. (1996). Handbook of Fluorescent Probes and Research Chemicals. 6th ed. Molecular Probes Inc., Eugene OR, p. 679
Hennes, K.P. and Suttle, CA. (1995). "Direct counts of viruses in natural waters and laboratory cultures by epifluorescence microscopy." Limno. Oceanogr. 40: 1050-1055.
Hennes, K.P. et al. (1995). "Fluorescently labeled virus probes show that natural virus populations can control the structure of marine microbial communities." Applied Environ. Microbiol. 61: 3623-3627.
Hirons, G.T. et al. (1994). "TOTO and YOYO: New very bright fluorochromes for DNA content analysis by flow cytometry." Cytom. 15: 129-140.
Holland, R.D. et al. (1996). "Rapid identification of intact whole bacteria based on spectral patterns using matrix assisted laser desorption ionization with time of flight mass spectrometry." Rapid Commun. Mass Spectrom. 10: 1227-1232.
Jing, J. et al. (1998). Automated high resolution optical mapping using arrayed, fluid-fixed DNA molecules. Proc. Natl. Acad. Sci. USA 95: 8046-51.
Kovacs, E. (1962). Chemical dissection of mammalian cells with liberation of biologically intact viruses. Z. Naturforschg. 17: 234-240.
Krishmanurthy, T. et al. (1996). "Detection of pathogenic and non-pathogenic bacteria by matrix assisted laser desorption ionization time of flight mass spectrometry." Rapid Commun. Mass Spectrom. 10: 883-888.
Liang, X. et al. (1996). "Determination of bacterial protein profiles by matrix assisted laser desorption ionization mass spectrometry with high performance liquid chromatography." Rapid Commun. Mass Spectrom. 10: 1219-1226.
Linnen, J. et al. (1996). "Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent." Science 271: 505-508.
Mazzone, H.M. (1998). CRC Handbook of Viruses. CRC Press, Boca Raton, p. 206.
National Cancer Institute Monograph 21, The Development of Zonal Centrifuges and Ancillary Systems for Tissue Fractionation and Analysis, U.S. Department of Health, Education and Welfare, Public Health Service, 1966
Samad, A.H. et al. (1995). "Mapping the genome one molecule at a time - optical mapping." Nature 378: 516-517.
Simons, J.N. et al. (1995). "Identification of two flavi- virus-like genomes in the GB hepatitis agent." Proc. Natl. Acad. Sci. USA 92: 3401-5.
Siuzdak, G. (1998). Probing viruses with mass spectrometry. J. Mass Spec. 33: 203-211.
Suttle, C. A. (1993). "Enumeration and isolation of viruses." In Handbook of Methods in Aquatic Microbial Ecology. Chapter 15. Kemp, P.F., Sherr, B.F., Sherr, E.B. and Cole, J.J., eds. Lewis Publishers, Boca Raton, Fla., pp 121-134.
Suttle, CA. and Chen, F. (1992). "Mechanisms and rates of decay of marine viruses in seawater." Appl. Environ. Microbiol. 58: 3721-3729. Wommack, K.E. et al. (1992). "Distribution of viruses in the Chesapeake Bay." Appl. Environ. Microbiol. 58: 2965-2970.
Yolken, R.H. and Torrey, E.F. (1996). "Viruses, schizophrenia and bipolar disorder." Clinical Microbiology Reviews 8: 131-145.
Zeuzem, S. et al. (1996). "Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology." Hepatology 24: 1003-1009.
Patents
U.S. Patent No. 3,519,400 U.S. Patent No. 4,106,907 U.S. Patent No. 4,624,835 U.S. Patent No. 4,861,477 U.S. Patent No. 5,342,790 U.S. Patent No. 5,422,018 U.S. Patent No. 5,489,396. U.S. Patent No. 5,558,998.

Claims

WHAT IS CLAIMED IS:
1. A system for measuring light emitted or scattered from a sample in a centrifuge tube wherein said system comprises: a centrifuge tube holder to hold the centrifuge tube in a vertical position; a light source which produces a beam of coherent polarized light; and a detector which detects light from said sample, a line of sight of said detector being normal to a plane defined by the electric component ofthe coherent polarized hght from said light source.
2. The system of claim 1, comprising in addition goniometers onto which said centrifuge tube holder is mounted thereby enabling a centrifuge tube which is in said centrifuge tube holder to be oriented to match the vertical angle ofthe beam of coherent polarized light; an X-Y movement to align the centrifuge tube with the beam of coherent polarized light in any X-Y direction; and a mirror to deflect said beam of coherent polarized light through the centrifuge tube held in said centrifuge tube holder.
3. The system of claim 1, wherein said detector detects light scatter from the sample.
4. The system of claim 1, further comprising a computer having a monitor.
5. The system of claim 1, wherein said light source is a laser.
6. The system of claim 1, further comprising a filter disposed between the sample and the detector, said filter for allowing only fluoresced light to pass therethrough.
7. A method for measuring light emitted or scattered from a sample in a centrifuge tube wherein said method comprises the steps of: centrifuging the centrifuge tube and sample to generate a microbanding zone thereby separating a portion ofthe sample; passing a beam of coherent polarized light through the centrifuge tube; detecting light emitted or scattered from said sample along a line of sight that is normal to a plane defined by the electric component ofthe coherent polarized light.
8. The method of claim 7, wherein scattered light from the sample is detected.
9. The method of claim 7, wherein the beam of coherent polarized light is generated by a laser.
10. The method of claim 7, further comprising the step of: filtering the light from the sample thereby detecting only fluorescent light.
11. The method of claim 7, wherein both scattered light and fluoresced light are independently detected.
PCT/US2001/027529 2000-09-08 2001-09-06 Method for detecting molecules or chemical reactions by determining variation of conductance WO2002021108A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001288762A AU2001288762A1 (en) 2000-09-08 2001-09-06 Detection and characterization of microorganisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65753100A 2000-09-08 2000-09-08
US09/657,531 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002021108A2 true WO2002021108A2 (en) 2002-03-14
WO2002021108A3 WO2002021108A3 (en) 2002-05-23

Family

ID=24637569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027529 WO2002021108A2 (en) 2000-09-08 2001-09-06 Method for detecting molecules or chemical reactions by determining variation of conductance

Country Status (2)

Country Link
AU (1) AU2001288762A1 (en)
WO (1) WO2002021108A2 (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465560B2 (en) 2004-11-30 2008-12-16 Purdue Research Foundation System and method for rapid detection and characterization of bacterial colonies using forward light scattering
DE102007058516A1 (en) * 2007-11-23 2009-06-04 Bruker Daltonik Gmbh Identification of pathogens in body fluids
WO2010062349A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for separation and characterization of microorganisms using identifier agents
WO2010062350A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for detection, characterization and/or identification of microorganisms in a sealed container
WO2010062356A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
WO2010062352A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for the isolation and identification of microorganisms
WO2010062354A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for separation, characterization, and/or identification of microorganisms using mass spectrometry
WO2010100612A1 (en) 2009-03-03 2010-09-10 Assistance Publique -Hôpitaux De Paris (Aphp) Method for identifying germs in a liquid medium
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8088582B2 (en) 2006-04-06 2012-01-03 Ibis Biosciences, Inc. Compositions for the use in identification of fungi
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8265878B2 (en) 2001-03-02 2012-09-11 Ibis Bioscience, Inc. Method for rapid detection and identification of bioagents
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
WO2013004674A1 (en) * 2011-07-05 2013-01-10 Boehringer Ingelheim Microparts Gmbh Method for measuring the scattered light of particles in a medium
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US8512975B2 (en) 2008-07-24 2013-08-20 Biomerieux, Inc. Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8551738B2 (en) 2005-07-21 2013-10-08 Ibis Biosciences, Inc. Systems and methods for rapid identification of nucleic acid variants
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8569010B2 (en) 2009-07-16 2013-10-29 Bruker Daltonik Gmbh Mass spectrometric diagnosis of septicemia
US8647835B2 (en) 2008-10-31 2014-02-11 BIO MéRIEUX, INC. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
US8748122B2 (en) 2008-12-16 2014-06-10 BIO MéRIEUX, INC. Methods for the characterization of microorganisms on solid or semi-solid media
US8787633B2 (en) 2007-01-16 2014-07-22 Purdue Research Foundation System and method of organism identification
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9080209B2 (en) 2009-08-06 2015-07-14 Ibis Biosciences, Inc. Non-mass determined base compositions for nucleic acid detection
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
EP3036523A1 (en) * 2013-08-20 2016-06-29 Advanced Polymer Monitoring Technologies Inc. Characterization of polymer and colloid solutions
US9393564B2 (en) 2009-03-30 2016-07-19 Ibis Biosciences, Inc. Bioagent detection systems, devices, and methods
US9416409B2 (en) 2009-07-31 2016-08-16 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US9719083B2 (en) 2009-03-08 2017-08-01 Ibis Biosciences, Inc. Bioagent detection methods
US9758840B2 (en) 2010-03-14 2017-09-12 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
JP2018163006A (en) * 2017-03-24 2018-10-18 株式会社日立ハイテクサイエンス Spectrophotofluorometer
EP2364218B1 (en) * 2008-10-31 2020-04-15 Biomerieux, Inc Container for the isolation and identification of microorganisms
CN113136412A (en) * 2021-04-22 2021-07-20 浙江珂瑞康生物医疗科技有限公司 Biological load determination treatment liquid for biomedical material containing soluble protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046047A2 (en) * 1998-03-10 1999-09-16 Large Scale Proteomics Corporation Detection and characterization of microorganisms
WO1999057533A1 (en) * 1998-05-01 1999-11-11 Crane Electronics Ltd. Simulated test joint for impulse tool testing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046047A2 (en) * 1998-03-10 1999-09-16 Large Scale Proteomics Corporation Detection and characterization of microorganisms
WO1999057533A1 (en) * 1998-05-01 1999-11-11 Crane Electronics Ltd. Simulated test joint for impulse tool testing

Cited By (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9752184B2 (en) 2001-03-02 2017-09-05 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8265878B2 (en) 2001-03-02 2012-09-11 Ibis Bioscience, Inc. Method for rapid detection and identification of bioagents
US9416424B2 (en) 2001-03-02 2016-08-16 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8815513B2 (en) 2001-03-02 2014-08-26 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents in epidemiological and forensic investigations
US8802372B2 (en) 2001-03-02 2014-08-12 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8921047B2 (en) 2001-06-26 2014-12-30 Ibis Biosciences, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8380442B2 (en) 2001-06-26 2013-02-19 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US9725771B2 (en) 2002-12-06 2017-08-08 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8476415B2 (en) 2003-05-13 2013-07-02 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8013142B2 (en) 2003-09-11 2011-09-06 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8288523B2 (en) 2003-09-11 2012-10-16 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8394945B2 (en) 2003-09-11 2013-03-12 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US9447462B2 (en) 2004-02-18 2016-09-20 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US9449802B2 (en) 2004-05-24 2016-09-20 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8987660B2 (en) 2004-05-24 2015-03-24 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US7465560B2 (en) 2004-11-30 2008-12-16 Purdue Research Foundation System and method for rapid detection and characterization of bacterial colonies using forward light scattering
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8551738B2 (en) 2005-07-21 2013-10-08 Ibis Biosciences, Inc. Systems and methods for rapid identification of nucleic acid variants
US8088582B2 (en) 2006-04-06 2012-01-03 Ibis Biosciences, Inc. Compositions for the use in identification of fungi
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8787633B2 (en) 2007-01-16 2014-07-22 Purdue Research Foundation System and method of organism identification
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
EP3543700A1 (en) 2007-11-23 2019-09-25 Bruker Daltonik GmbH Identification of pathogens in body fluids
EP3543700B1 (en) 2007-11-23 2020-12-30 Bruker Daltonik GmbH Identification of pathogens in body fluids
EP2837940A1 (en) 2007-11-23 2015-02-18 Bruker Daltonik GmbH Identification of pathogens in body fluids
DE102007058516B4 (en) * 2007-11-23 2017-08-10 Bruker Daltonik Gmbh Identification of pathogens in body fluids
EP4220168A2 (en) 2007-11-23 2023-08-02 Bruker Daltonics GmbH & Co. KG Identification of pathogens in body fluids
US8450081B2 (en) 2007-11-23 2013-05-28 Bruker Daltonik Gmbh Identification of pathogens in body fluids
DE102007058516A1 (en) * 2007-11-23 2009-06-04 Bruker Daltonik Gmbh Identification of pathogens in body fluids
US8709748B2 (en) 2008-07-24 2014-04-29 Biomerieux, Inc. Method for detection and characterization of a microorganism in a sample using time-dependent intrinsic fluorescence measurements
US10435733B2 (en) 2008-07-24 2019-10-08 Biomerieux, Inc. Method and system for detection and/or characterization of a biological particle in a sample
US8512975B2 (en) 2008-07-24 2013-08-20 Biomerieux, Inc. Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8609430B2 (en) 2008-09-16 2013-12-17 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9027730B2 (en) 2008-09-16 2015-05-12 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US9023655B2 (en) 2008-09-16 2015-05-05 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8252599B2 (en) 2008-09-16 2012-08-28 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
CN102272602A (en) * 2008-10-31 2011-12-07 生物梅里埃公司 Methods for the isolation and identification of microorganisms
US10415075B2 (en) 2008-10-31 2019-09-17 Biomerieux, Inc. Method for separation, characterization and/or identification of microorganisms using mass spectrometry
CN102317789A (en) * 2008-10-31 2012-01-11 生物梅里埃公司 Utilize the method for mass spectroscopy separation, sign and/or Identifying micro-organisms
WO2010062354A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for separation, characterization, and/or identification of microorganisms using mass spectrometry
CN102272601A (en) * 2008-10-31 2011-12-07 生物梅里埃公司 Methods for separation and characterization of microorganisms using identifier agents
WO2010062352A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for the isolation and identification of microorganisms
WO2010062349A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for separation and characterization of microorganisms using identifier agents
US10059975B2 (en) 2008-10-31 2018-08-28 Biomerieux, Inc. Methods for the isolation and identification of microorganisms
US10167494B2 (en) 2008-10-31 2019-01-01 Biomerieux, Inc. Method for detection, characterization and/or identification of microorganisms in a sealed container
CN102272602B (en) * 2008-10-31 2014-03-12 生物梅里埃公司 Methods for isolation and identification of microorganisms
US8652800B2 (en) 2008-10-31 2014-02-18 Biomerieux, Inc. Method for separation, characterization and/or identification of microorganisms using spectroscopy
US9790534B2 (en) 2008-10-31 2017-10-17 Biomerieux, Inc. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
US9128058B2 (en) 2008-10-31 2015-09-08 Biomerieux, Inc. Method for separation and characterization of microorganisms using identifier agents
US8647835B2 (en) 2008-10-31 2014-02-11 BIO MéRIEUX, INC. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
WO2010062350A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for detection, characterization and/or identification of microorganisms in a sealed container
EP2364218B1 (en) * 2008-10-31 2020-04-15 Biomerieux, Inc Container for the isolation and identification of microorganisms
AU2009320330B2 (en) * 2008-10-31 2016-01-07 Biomerieux, Inc. Methods for separation and characterization of microorganisms using identifier agents
JP2012507710A (en) * 2008-10-31 2012-03-29 バイオメリュー・インコーポレイテッド Method for the separation, characterization and / or identification of microorganisms using identification agents
WO2010062356A1 (en) * 2008-10-31 2010-06-03 Biomerieux, Inc. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
US8748122B2 (en) 2008-12-16 2014-06-10 BIO MéRIEUX, INC. Methods for the characterization of microorganisms on solid or semi-solid media
US8795983B2 (en) 2008-12-16 2014-08-05 Biomerieux, Inc. Methods for the characterization of microorganisms on solid or semi-solid media
US9822389B2 (en) 2008-12-16 2017-11-21 bioMerièux, Inc Method for the characterization of microorganisms on solid or semi-solid media
US9165740B2 (en) 2009-02-12 2015-10-20 Ibis Biosciences, Inc. Ionization probe assemblies
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8796617B2 (en) 2009-02-12 2014-08-05 Ibis Biosciences, Inc. Ionization probe assemblies
CN102395680A (en) * 2009-03-03 2012-03-28 公共救济事业局-巴黎医院 Method for identifying germs in a liquid medium
FR2942806A1 (en) * 2009-03-03 2010-09-10 Assist Publ Hopitaux De Paris METHOD FOR IDENTIFYING GERMS IN A LIQUID ENVIRONMENT
JP2012519479A (en) * 2009-03-03 2012-08-30 アシスターンス ピュブリク−オピト ドゥ パリ (アペアシュペ) Identification method of pathogenic bacteria in liquid medium
WO2010100612A1 (en) 2009-03-03 2010-09-10 Assistance Publique -Hôpitaux De Paris (Aphp) Method for identifying germs in a liquid medium
US9719083B2 (en) 2009-03-08 2017-08-01 Ibis Biosciences, Inc. Bioagent detection methods
US9393564B2 (en) 2009-03-30 2016-07-19 Ibis Biosciences, Inc. Bioagent detection systems, devices, and methods
US8569010B2 (en) 2009-07-16 2013-10-29 Bruker Daltonik Gmbh Mass spectrometric diagnosis of septicemia
AU2010272586B2 (en) * 2009-07-16 2013-12-05 Bruker Daltonics GmbH & Co. KG Mass spectrometric diagnosis of septicemia
US11473122B2 (en) 2009-07-16 2022-10-18 Bruker Daltonik Gmbh Mass spectrometric diagnosis of septicemia
EP2454377B2 (en) 2009-07-16 2021-05-26 Bruker Daltonik GmbH Mass spectrometric diagnosis of septicemia
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US9416409B2 (en) 2009-07-31 2016-08-16 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
US10119164B2 (en) 2009-07-31 2018-11-06 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
US9080209B2 (en) 2009-08-06 2015-07-14 Ibis Biosciences, Inc. Non-mass determined base compositions for nucleic acid detection
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
US9758840B2 (en) 2010-03-14 2017-09-12 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
WO2013004674A1 (en) * 2011-07-05 2013-01-10 Boehringer Ingelheim Microparts Gmbh Method for measuring the scattered light of particles in a medium
EP3036523A4 (en) * 2013-08-20 2017-04-05 Advanced Polymer Monitoring Technologies Inc. Characterization of polymer and colloid solutions
EP3036523A1 (en) * 2013-08-20 2016-06-29 Advanced Polymer Monitoring Technologies Inc. Characterization of polymer and colloid solutions
US9664608B2 (en) 2013-08-20 2017-05-30 Advanced Polymer Monitoring Technologies, Inc. Characterization of polymer and colloid solutions
JP2018163006A (en) * 2017-03-24 2018-10-18 株式会社日立ハイテクサイエンス Spectrophotofluorometer
CN113136412A (en) * 2021-04-22 2021-07-20 浙江珂瑞康生物医疗科技有限公司 Biological load determination treatment liquid for biomedical material containing soluble protein

Also Published As

Publication number Publication date
WO2002021108A3 (en) 2002-05-23
AU2001288762A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
US6254834B1 (en) Detection and characterization of microorganisms
WO2002021108A2 (en) Method for detecting molecules or chemical reactions by determining variation of conductance
US8679764B2 (en) Density-based cell detection system
US8383419B2 (en) Harvesting target materials from centrifuged suspensions
CN1221805C (en) Method and apparatus for separating shaped compositions from composition of complex biological liquid sample
US7713744B2 (en) Determining the risk of cardiovascular disease using ion mobility of lipoproteins
JP2020110175A (en) Automated system for processing particles
US20130157283A1 (en) Rapid pathogen diagnostic device and method
JP2004530877A (en) Method and apparatus for using optical forces for particle identification, characterization and / or sorting
JP2002528699A (en) Microfabricated cell sorter
US6933109B2 (en) Rapid particle detection
AU2003302333A1 (en) Methods and apparatus for electrosmear analysis
US5403714A (en) Method for in vitro detection of formed elements in biological samples
Ferris et al. Quantitative intercomparison of transmission electron microscopy, flow cytometry, and epifluorescence microscopy for nanometric particle analysis
Skinner et al. Simplified confocal microscope for counting particles at low concentrations
US4414197A (en) Method for preparing permanent slides of rare sorted cells
DE19631855C2 (en) Method and device for the detection of surface antigens or structural features of cells, particles or macromolecules
MXPA00008845A (en) Detection and characterization of microorganisms
US20080000284A1 (en) Systems and methods for centrifuge sample holders
JPS61292057A (en) Device and method of removing fraction
Anderson THE VIROME PROJECT, A “MANHATTAN PROJECT’FOR BIOTERRORISM. II. TECHNIQUES FOR PHYSICAL VIRUS DETECTION USING MICROBANDING TUBES Version 1.0
Wells [24] Cell separation using velocity sedimentation at unit gravity and buoyant density centrifugation
CN112384802A (en) Device and method for determining the concentration of particles in a sample

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 300104)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP